Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with Pseudomonas aeruginosa by Pattison, SH et al.
Proteomic profile of cystic fibrosis sputum cells in adults 
chronically infected with Pseudomonas aeruginosa 
Journal: European Respiratory Journal 
Manuscript ID ERJ-01569-2016.R1 
Manuscript Type: Original Article 
Date Submitted by the Author: 15-Mar-2017 
Complete List of Authors: Pattison, Sally; Queen's University Belfast, Centre for Infection and 
Immunity 
Gibson, David; Queen's University Belfast, Centre for Infection and 
Immunity 
Johnston, E; Queen's University Belfast, Centre for Infection and Immunity 
Peacock, Samantha; Cold Spring Harbor Laboratory, Pappin Laboratory 
Rivera, Keith; Cold Spring Harbor Laboratory, Pappin Laboratory 
tunney, michael; Queen's University Belfast, School of Pharmacy 
Pappin, Darryl; Cold Spring Harbor Laboratory, Pappin Laboratory 
Elborn, J; Queen's University Belfast, Centre for Infection and Immunity 
Key Words: cystic fibrosis and chronic infections, sputum, proteomics 
European Respiratory Journal
Reviewer: 1 
Comments to the Author –  
This is an interesting paper using a novel -omics Technology to study CF Airway 
inflammation. 
While the approach, the originality and Interpretation of the findings are sound and of high 
quality, there Are several issues that should Be Adressed: 
Reviewer 1 Comment 1: the number of included CF Patients is low, which is 
understandable given the omics approach. However, As ERJ is a clinically-focused rather 
than a biochemical Journal, this part should be strenghtened, for instance: (i) include 
additional CF Patient samples, (ii) add some longitudinal analyses, (iii) add a disease control 
Group for instance COPD or BE, (iv) add some BAL samples (If available) to validate their 
findings in sputum. 
Reviewer 1 Response 1: Our study was a clinically-focused investigation of the potential 
mechanisms for lung damage in adults with cystic fibrosis. It uniquely studied the protein 
abundance of cells in vivo, thereby taking into account both their natural frequency in the 
sputum cell population and the effects of intercellular interactions. Thus, it delivers a high 
degree of clinical relevance to our findings. The manuscript has been revised to include a 
more detailed analysis of longitudinal samples for each of the CF patients enrolled in the 
study. Furthermore, we have analysed the changes in sputum total protein yield (mg per g 
sputum) and differential relative abundance in individual proteins of interest during 
intravenous antibiotic treatment of pulmonary exacerbation. In both cases we observed that 
antibiotic treatment of exacerbation is associated with proteomic changes to more closely 
resemble the healthy control cohort. We have also observed that at the follow-up sample 
collection total protein yield returned to levels similar to exacerbation pre-treatment levels.  
Given cost and time restrictions, we have focused exclusively on CF. However, if further 
funding were to come available, we would like to expand our investigation to include other 
cohorts.  
Reviewer 1 Comment 2: The authors identified interesting correlations for AAT and 
Olfactomedin-4 in their small CF cohort. The authors could go on and validate the broader 
clinical usefulness of These markers in a larger CF patient cohort. 
Reviewer 1 Response 2: While we agree that it would be extremely interesting to follow-up 
on candidate biomarkers identified by our study, such as alpha-1-antitrypsin and 
olfactomedin-4, the scope of our study was exploratory. We aimed to investigate for the first 
time the global proteome of the combined population of cells present in CF sputum in order 
to assess their potential hazard through cell activities and/or release into sputum fluid. We 
have highlighted the exploratory nature of the study and our acknowledgement of this 
limitation has generally been recognised by the reviewers in light of the novel proteomics 
approach both in terms of technology and the previously unstudied cell population that more 
accurately represents the CF lung than previous studies of single cell type in vitro cultures or 
animal models. We do not currently have ethical approval and funding to expand its scope or 
for the increased patient recruitment which would be required in order to investigate a larger 
CF patient cohort. However, in response to reviewer’s comments we have undertaken 
additional laboratory analysis using our existing sample set to validate findings using 
commercial ELISAs and so have demonstrated that commercial ELISAs are a practical high-
throughput method suitable for independent, large-scale validation of candidate biomarkers 
identified by this study.  
Reviewer 1 Minor points – 
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Reviewer 1 Comment 3: introduction and Discussion could include more Refs on 
neutrophils in CF 
Reviewer 1 Response 3: While we agree that neutrophils play an important role in CF, our 
study investigated all cell types found in CF sputum and we feel that to comment specifically 
on neutrophils would require us to comment on all cells likely to be present in our samples. 
Unfortunately we are unable to do this due to journal requirements that restrict the number of 
references. Also, we wished to avoid lengthening the manuscript. 
Reviewer 1 Comment 4:  Ref 38 should Be substituted, for instance with Manzenreiter et al 
JCF and/or Marcos et al. Mediators of Inflammation 2015. 
Reviewer1 Response 4: Thank you for your suggestion. We have now substituted the 
following reference- 
Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Krautgartner WD, Stoiber W, 
Griese M, Eickelberg O, Mall MA, Hartl D. Free DNA in cystic fibrosis airway fluids correlates 
with airflow obstruction. Mediators Inflamm 2015; 2015:408935. 
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Reviewer: 2 
Comments to the Author 
This is a proteomic study of 12 adult patients with cystic fibrosis. I enjoyed reading the 
paper, and it is likely to be very interesting as a hypothesis generating manuscript for those 
searching for CF biomarkers. The paper is very nicely written and easy to follow.  
Comments 
Reviewer 2 Comment 1:  Early in the manuscript (perhaps even in the title) and in some 
parts of the discussion, it would be nice to be clear that the conclusions in the paper are 
relevant to "adult CF patients with P. aeruginosa colonisation". The proteome results here 
cannot be used to make conclusions about "CF" but rather about "adult CF patients with P. 
aeruginosa infection".  
Reviewer 2 Response 1: We have amended the title of the manuscript to “Proteomic profile 
of cystic fibrosis sputum cells in adults chronically infected with Pseudomonas aeruginosa”. 
In addition we have now recognised this study limitation more consistently throughout the 
manuscript. 
Reviewer 2 Comment 2:  Did the authors perform any comparisons of proteomic data 
between stability and exacerbation?  
Reviewer 2 Response 2: The manuscript has been revised to include a more detailed 
analysis of longitudinal samples collected over the course of intravenous antibiotic treatment 
of pulmonary exacerbation. Accordingly, a new results section entitled “Longitudinal analysis 
of antibiotic treatment of exacerbation” has been added and the findings commented on in 
the discussion. 
Reviewer 2 Comment 3:  How do the authors differentiate between NET proteins and those 
that are simply released from neutrophils during cell death or lysis during the protein 
extraction process? I accept that prior studies have found NETS in the CF lung, but it seems 
speculative to say these proteins are NETs (unless the authors have some data to show that 
specific neutrophil proteins are increased relative to other neutrophil proteins that are not 
implicated in NETs). This issue also leads into point 4 
Reviewer 2 Response 3: From our data we cannot definitively say that any of the proteins 
detected were NET proteins and indeed we have explicitly stated in our manuscript 
discussion (P16) that as “our study focused on sputum cellular proteins we did not look 
specifically for NET structures, which are extracellular, and therefore do not know if they 
were present.” Instead, what we have reported is the consistently high abundance in sputum 
cells of proteins which are known to be the main constituents of NETs. Although we cannot 
know the fate of these cellular proteins, NETs are a recognised phenomenon in CF and we 
think it is reasonable to suggest that they could pose a significant hazard if indeed they were 
released as NETs. However, in order to avoid misinterpretation of our discussion of this 
potential hazard we have revised wording where appropriate throughout the manuscript. 
Reviewer 2 Comment 4:  It is a shame that some of the candidates were not validated by 
ELISA, but the authors have acknowledged this issue. None of the identified candidates can 
be considered biomarkers until validated. I think largely the authors have largely addressed 
this well (except for the speculation about NETs above).  
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Reviewer 2 Response 4: As explained in Response 2 to Reviewer 1, we agree that it would 
be extremely interesting to follow-up on candidate biomarkers identified by our study in a 
large independent cohort. As a first step towards such validation, we have performed and 
detailed in the manuscript additional laboratory analysis of our existing sample set to confirm 
findings for two candidate biomarkers, myeloperoxidase and lactotransferrin. Thus, we have 
demonstrated the potential of commercial ELISAs for further validation of candidate 
biomarkers in an independent large-scale study. We have highlighted the exploratory nature 
of our study and our acknowledgement of this limitation has been generally recognised by 
the reviewers in light of the novel proteomics approach both in terms of technology and the 
previously unstudied cell population.  
 
 
Reviewer 2 Comment 5:  I believe reference 38 has been retracted. It is bad practice to 
reference papers that have been retracted.  
 
Reviewer 2 Response 5: We have now substituted the following reference – 
 
Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Krautgartner WD, Stoiber W, 
Griese M, Eickelberg O, Mall MA, Hartl D. Free DNA in cystic fibrosis airway fluids correlates 
with airflow obstruction. Mediators Inflamm 2015; 2015:408935. 
 
 
Reviewer 2 Comment 6:  The discussion of the negative effects of alpha-1 and 
olfactomedin 4 in CF in the discussion are a bit simplistic - the reality of inflammation is that 
both pro and anti-inflammatory molecules are released concurrently during inflammation, 
and so the implication the authors make that because they are associated with lung function 
they are likely to be harmful might be true, but it is equally possible these are "innocent 
bystanders" or an ineffective counter-response. (when the house is on fire, the equivalent of 
proteomics might detect fire-trucks, but it doesn't mean the fire trucks are causing the 
fire.....)  
 
Reviewer 2 Response 6: We agree that a negative correlation with lung function does not 
prove causation and have revised the manuscript to clarify this.    
 
 
Reviewer 2 Comment 7:  The introduction is relatively long and i feel some of the last 
couple of paragraphs could be moved to the discussion. As a minor point, ERJ does not 
require the acknowledgement of abstract publications (this is a AJRCCM requirement) so 
this could be removed.  
 
Reviewer 2 Response 7: We have shortened the manuscript’s introduction as suggested. 
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Reviewer: 3 
 
Comments to the Author 
 
The information about the global proteome of cells present in CF sputum may integrate the 
data concerning the extracellular proteome of this fluid. The present manuscript appears as 
a preliminary report describing the proteome analysis of sputum cells from these patients. As 
such, the identification of the most abundant cellular proteins is indeed of interest for gaining 
further understanding of the mechanisms underlying this severe lung disease. 
In my opinion this is the novelty of the present manuscript that, in other respects, follows the 
“conventional” procedure of several similar articles: identification of a large list of proteins, 
some of which are indicated as candidate biomarkers for disease status. A great deal of 
future research will obviously be needed to validate these data. Thus, while not having 
impressed me that much, this article is well-written and science is good.  
Nevertheless, I have two major concerns: 
        
Reviewer 3 Comment 1: The major limitation of this study is represented by the very small 
cohort of individuals analyzed, also in the light of the dishomogeneity of patients considered. 
As shown in the demographic table, two of them have very high FEV1 values and two very 
low. If the FEV1 values reflect the severity of the disease (i.e. lung conditions), then one can 
imagine that the “starting” conditions of these people are not the same. Most likely also in 
terms of cellular proteome. The authors state that “Lung function was measured as FEV1 % 
predicted prior to each sputum collection. This was done to encompass all aspects of CF 
lung health and prevent proteome bias towards any particular clinical status” but what does 
this mean ? This sentence is ambiguous. It should be re-formulated and moved at the 
beginning of the Results section indicating the reasons why these patients  have formed a 
“group”. However, I wonder whether these data may be actually representative of the 
proteome of cells present in CF sputum.  
 
Reviewer 3 Response 1: The inclusion criteria for our study limited the CF cohort to adults 
with Pseudomonas aeruginosa infection. We agree that other criteria could also have been 
applied to specify the cohort further, but this would have further limited the clinical relevance 
of our findings. We aimed to investigate more broadly the sputum cellular proteome of adults 
with CF chronically infected with P. aeruginosa.  Therefore, not only do the FEV1 values of 
the CF cohort vary, but we have also deliberately included in our analysis samples collected 
at different times of clinical health for each individual. The inclusion of this range of samples 
is what we are referring to with the statement “This was done to encompass all aspects of 
CF lung health and prevent proteome bias towards any particular clinical status.” As 
requested we have clarified this further at the start of the results section of the revised 
manuscript. 
 
 
Reviewer 3 Comment 2: Given that the number of males and females in the patient’s cohort 
is almost the same, it is not clear to me the reason why the control group is made by a 
number of females that is two-fold higher than that of males. I think that finding a number of 
healthy males/females comparable to that of patients was likely not such a big problem. 
While being aware that the real discrimination is between the proteome of healthy and CF 
patients, I wonder whether this gender difference may not introduce an additional variable. 
 
Reviewer 3 Response 2: We agree complete age and sex matching between control and 
patient groups would be desirable but there is no evidence here of a sex bias in the data for 
either group. 
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Reviewer: 4 
 
Comments to the Author 
 
In this paper, Pattison et al presents a Multidimensional Protein Identification Technology 
that is applied to analyse sputum cellular proteins from Cystic fibrosis patients in comparison 
to  healthy controls. By utilizing Ingenuity Pathway Analysis, Gene Ontology functions, 
protein abundance and correlation, claims are made on clinical significance.of the candidate 
proteins identified in the study. 
 
There are a number of unclear parts within this study that makes the results and claims 
made questionable. The n-numbers of the patients are really low in order to reach statistical 
significance here, and it’s a major issue with the study. Additional considerations needs to be 
made before the paper can be considered for further Editorial processing, and they are as 
follows; 
 
Reviewer 4 Comment 1:  How was the samples normalized. Usually the sputum samples 
are highly heterogeneous, what the status in this study. Already when you mention plugs it’s 
a challenge to get similar samples to be comparable 
 
Reviewer 4 Response 1 (N.B. Since the second point above expands on the concern 
about sample heterogeneity raised in the first point we have combined our response): 
As with all sputum samples, the samples collected for this study were heterogeneous. 
However, our study followed standardised procedures for the processing of all samples 
including processing by the same researcher under the same conditions using the same 
equipment in order to minimise technical variation. Additionally, an equal amount of protein 
per sample (70 µg) was analysed by mass spectrometry and our data analyses examined 
the relative protein composition of sputum cells which a lower cell density in one plug 
compared to another would not affect.  
 
 
Reviewer 4 Comment 2: How did you manage to solubilize the samples. After experimental 
prepp. steps, what was the non-soluble fraction of each and every sputum sample ? 
 
Reviewer 4 Response 2: As outlined in the Methods section of the Supplementary Data the 
cells were lysed in a buffer consisting of 10 mM HEPES, 0.5 mM EDTA, 1% v/v Nonidet P 
40, 4% w/v SDS, pH 8.0, which also served to solubilise the proteins. We did not analyse the 
non-soluble fraction. 
 
 
Reviewer 4 Comment 3: How did you build a reliable sample preparation methodology – 
here? I miss out on Recovery data, reproducibility and rigidity of the sample preparation is 
crucial. If this step is not solid, the entire Expression study is questionable. 
 
Reviewer 4 Response 3: As already indicated in Response 1 to Reviewer 4, our protocols 
were standardised and followed rigidly to reduce technical variability. As requested, the total 
protein yield for each sample (mg per g of sputum) has now been added to the revised 
manuscript in Figure E1 in the online supplement. We agree that consistent sample 
preparation is key to expression studies and believe that Fig. 1, which shows that protein 
profiles tended to cluster by CF individual despite sample collection and processing on 
separate days, demonstrates that reproducibility was achieved in our study. Further 
evidence of method reproducibility is provided by the consistent pattern for each CF 
participant of a decrease in protein yield (mg per g of sputum) after antibiotic treatment of 
exacerbation, followed by a return to higher levels in the stable sample for 11/12 
participants, as shown in Figure E1. 
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Reviewer 4 Comment 4: How did you normalize the samples How did you manage to 
correlate the patient groups here to make them comparable in the study. 
 
Reviewer 4 Response 4 (since the above points are linked we have made one 
response): As described in the Methods section of the Supplementary Data, 70ug of soluble 
protein was trypsin-digested and iTRAQ labelled per sample and six samples plus a 
reference were combined in each mass spectrometry run.  Each run’s internal reference was 
then used to normalise the samples to obtain a relative abundance for each protein (relative 
to the reference) per sample. Normalisation to the reference sample allowed us to compare 
between cohorts. This process has been clarified in the Statistical analyses section. 
 
 
Reviewer 4 Comment 5: Another remark by this reviewer is that the numbers of patient 
samples are really low in order to make any conclusionsQ. 
 
Reviewer 4 Response 5: We have explicitly acknowledged in our manuscript that our study 
has a relatively low sample size and explained that this is the inevitable trade-off for a 
quantitative, high proteome coverage analysis of sputum cells as a novel target. We have 
additionally explained in the manuscript that while cohort size limits the scope of our study 
conclusions, the findings are of exploratory interest and may have future clinical value if 
validated in a larger study. In general, the reviewers have accepted our justification of this 
limitation to our study. 
 
 
Reviewer 4 Comment 6: I think its unacceptable in 2016 to present page don and page up 
of annotated and regulated proteins from 12 patients when you have no Validation, except 
for 2 WB experimentsQ.. 
-       Further to the above, you state on page 5; 
Differentially abundant proteins related to Rho family small GTPase activity, immune cell 
movement/activation, generation of reactive oxygen species and the dysregulation of cell 
death and proliferation. Compositional breakdown established neutrophil extracellular trap 
associated proteins as consistently detected in high abundance. A further 17 proteins 
correlated negatively with lung function”. 
Further, you continue; 
These findings expand current understanding of the mechanisms underlying inflammatory 
drivers in CF lung disease and identify sputum cellular proteins with potential for use as 
markers of disease status, prognostic indicators, stratification determinants for treatment 
prescription or as therapeutic targets.”  
This reviewer cannot find data that supports the valiudity of the se claims made here. It 
seems that to fulfil these, another much bigger validation study needs to be put in place to 
support the data in this study. 
•       The claims made are simply not possible to prove with statistical significance 
•       I would like the authors to have a view on the protein regulation and the disease 
biology Q 
 
Reviewer 4 Response 6 (as the above points are linked we have made one response): 
The discovered proteins indeed act as a set of candidates which we agree requires a much 
larger and correctly powered follow-up validation study. In response to reviewer’s comments, 
we have undertaken additional laboratory work and validated the findings in our existing 
cohort using commercial ELISAs. Moreover, we have demonstrated that commercial ELISAs 
are a practical high-throughput method suitable for future independent, large-scale validation 
of candidate biomarkers identified by our study.  
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Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with 
Pseudomonas aeruginosa 
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Rivera,2 Michael M. Tunney,3 Darryl J. Pappin,2 and J. Stuart Elborn1 
 
1 Centre for Infection and Immunity, Queen’s University Belfast, Belfast, Northern 
Ireland, BT9 7BL, UK.  
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 School of Pharmacy, Queen’s University Belfast, Belfast, Northern Ireland, BT9 
7BL, UK. 
 
Corresponding Author: Dr Sally Pattison, Centre for Infection and Immunity, Medical 
Biology Centre, 97 Lisburn Road, Queen’s University Belfast, N. Ireland, BT9 7BL, 
UK. Email: s.pattison@qub.ac.uk. Phone: (+44) 028 9097 2698 
 
Take-Home Message: CF sputum proteomics detects high abundance of NET 
proteins and identifies proteins correlating negatively with %FEV1. 
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ABSTRACT 
Lung disease is the main cause of morbidity and mortality in cystic fibrosis (CF) and 
involves chronic infection and perturbed immune responses. Tissue damage is 
mediated mostly by extracellular proteases, but other cellular proteins may also 
contribute to damage through their effect on cell activities and/or release into sputum 
fluid by means of active secretion or cell death.  
We employed Multidimensional Protein Identification Technology to identify sputum 
cellular proteins with consistently altered abundance in adults with CF, chronically 
infected with Pseudomonas aeruginosa, compared to healthy controls. Ingenuity 
Pathway Analysis, Gene Ontology, protein abundance and correlation with lung 
function were used to infer their potential clinical significance.  
Differentially abundant proteins relate to Rho family small GTPase activity, immune 
cell movement/activation, generation of reactive oxygen species and dysregulation of 
cell death and proliferation. Compositional breakdown identified high abundance of 
proteins previously associated with neutrophil extracellular traps. Furthermore, 
negative correlations with lung function were detected for 17 proteins, many of which 
have previously been associated with lung injury.  
These findings expand current understanding of the mechanisms driving CF lung 
disease and identify sputum cellular proteins with potential for use as indicators of 
disease status/prognosis, stratification determinants for treatment prescription or as 
therapeutic targets.  
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INTRODUCTION 
The lack or reduced presence at cell surfaces of fully functional cystic fibrosis 
conductance regulator (CFTR) in people with cystic fibrosis (CF) results in a build-up 
of dense, dehydrated mucus that promotes infection and thus, chronic inflammation 
[1]. Additionally, CF has been labeled a mucosal immunodeficiency syndrome 
because of the direct proinflammatory effects of CFTR dysfunction on the 
dysregulation of epithelial innate immunity and airway leukocytes [2]. As such, the 
pathophysiology of the CF lung is highly complex, involving numerous interactions 
between multiple human cell types and a diverse microbiota [3-5], as well as the 
inherent impairment of several cell types.  
Proteomic studies of the CF airways have investigated protein abundance in 
epithelial cells cultured in vitro or obtained from animal models or clinical samples [6-
13]. Furthermore, several studies have assessed the extracellular proteomes of CF 
sputum, bronchoalveolar lavage fluid (BALF) and bronchial epithelial cell secretions 
[14-19]. The main observations of these studies are summarised in the online 
supplement (Table E1). Although these studies have all contributed to our 
understanding of CF, investigations of single cell types, in vitro cultures and animal 
models have limited relevance to in situ CF lung pathogenesis. To date, the 
contribution of the global proteome of all cell types in the proportions occurring 
naturally in CF sputum has not been investigated. We hypothesized that proteins 
detected in sputum cells can have a detrimental effect on CF lung health, both 
through their effect on cell functioning and activities, and through their release into 
extracellular sputum fluid by means of active secretion or cell death. 
We employed quantitative comparative proteomics to characterise the global activity 
and protein composition of cells in CF sputum from adults chronically infected with P. 
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aeruginosa to provide insight into potential mechanisms of lung disease and to 
identify candidate biomarkers associated with poor lung function in this population. 
By employing these methods we were able to identify, in clinical samples, novel 
cellular proteins and activities likely to be clinically relevant as mechanisms for tissue 
damage and disease progression.  
 
METHODS 
Study participants 
Twelve adults with CF, aged 26.8 ± 5.98 (mean ± SD; range 18-37) were recruited at 
Belfast City Hospital on admission for treatment with intravenous antibiotics for an 
acute pulmonary exacerbation as defined by Fuchs et al. [21]. Seven were male and 
five female. All were chronically infected with P. aeruginosa. Their characteristics 
and treatment regimens are recorded in Table 1 and Table E2 (online supplement), 
respectively. Three induced sputum samples were collected from each CF 
participant at times of differing clinical status – untreated pulmonary exacerbation, 
within 24h of completing intravenous antibiotic treatment of exacerbation and 4-15 
weeks after completion of treatment. Lung function was measured as FEV1 % 
predicted prior to each sputum collection. Twelve non-smoking, healthy control 
participants, aged 29.6 ± 4.27 (mean ± SD; range 25-39) were recruited. Eight were 
female and four male. A single induced sputum sample was collected from each 
control individual. Ethical approval for this study was granted by the Office for 
Research Ethics Committees Northern Ireland (Ref: 09/NIR02/68) and informed 
consent was obtained from all subjects. 
  
Page 12 of 118European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 5 
 
Age M/F PEx (previous 12 months) % FEV1 CFTR Genotype 
CF1 23 F 2 35-36 F508del/ F508del 
CF2 36 F 0 26-36 F508del/ F508del 
CF3 31 M 1 81-102 F508del/G551D 
CF4 18 M 1 57-69 F508del/ F508del 
CF5 25 M 2 52-60 F508del/ F508del 
CF6 37 F 0 51-62 F508del/ F508del 
CF7 28 M 0 26-30 F508del/ F508del 
CF11 29 F 1 49-75 F508del/ F508del 
CF12 22 M 2 31-41 F508del/ F508del 
CF13 19 M 1 55-77 F508del/ F508del 
CF15 28 F 1 73-98 F508del/R117H 
CF16 26 M 1 40-54 F508del/ F508del 
 
Table 1: Characteristics of the CF cohort. % FEV1 records the range measured over 
the 3 sputum collections. 
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Sample preparation 
For each sputum sample the cell population was harvested from mucus plugs, 
washed and proteins extracted. Briefly, approximately 1g of mucus plug was 
homogenised thoroughly with 9 ml sterile phosphate buffered saline and the cells 
pelleted by centrifugation. Following two further wash steps and cell straining to 
remove clumps, the cells were pelleted to remove all traces of supernatant. The 
pellet was then homogenised thoroughly in lysis buffer and subjected to repeated 
freeze-thaw and water bath sonication to ensure cell lysis. Insoluble debris was 
removed by centrifugation. All work was carried out at 4⁰C and in the presence of a 
protease inhibitor cocktail. Full method details are given in the online supplement. 
Proteomic methods 
Protein digestion and iTRAQ labelling were performed as described previously {{904 
Scuoppo,C. 2012}} and details are recorded in the online data supplement. Protein 
digestion with trypsin and labelling with 8plex iTRAQ Reagents (AB Sciex) were 
performed as described previously [22]. Six test samples and a reference sample 
were mixed for simultaneous analysis by 2D liquid chromatography MudPIT on line 
with an LTQ Orbitrap Velos (Thermo Electron) as described previously [22]. Further 
details of the methods employed for MudPIT are recorded in the online data 
supplement. 
Protein identification 
Peaklists were generated by Mascot Distiller and protein identification was 
performed by the Mascot search engine against the UniProt database plus NCBI 
non-redundant database, taxonomy P. aeruginosa. Further details of the methods 
used in protein identification are recorded in the online data supplement. The mass 
spectrometry proteomics data have been deposited to the ProteomeXchange 
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Consortium [23] via the PRIDE partner repository with the dataset 
identifier PXD001985 and 10.6019/PXD001985. Western immunoblot and enzyme-
linked immunosorbent assay (ELISA) were used to confirm the mass spectrometry 
identification and quantification data as described in the online data supplement.  
Statistical analyses 
SPSS was used for all statistical analysis unless otherwise stated. iTRAQ sample 
labels were used to calculate each protein’s abundance per sample relative to the 
reference included in each mass spectrometry run, thus enabling comparison of 
protein abundance between samples. Hierarchical clustering of sample protein 
profiles was performed by PermutMatrix [24] using Euclidean distance dissimilarity 
and McQuitty’s linkage criteria. Prior to cluster analysis proteins within the dataset 
were tested for collinearity (Bivariate Spearman correlation coefficient >0.9) and four 
proteins that correlated highly with others were subsequently excluded. Independent 
samples T-tests and Mann Whitney U tests were performed to identify differentially 
abundant proteins (p<0.05) between the CF and control cohorts. Ingenuity Pathway 
Analysis (IPA) was then employed to predict: (a) Canonical Pathway activity in both 
the CF and control consensus core proteomes (Fisher’s Exact Test); (b) altered Bio 
Function activity in CF relative to the control group (Fisher’s Exact Test); (c) Bio 
Function up- or down-regulation in CF (IPA Regulation z-score algorithm).  
For proteins detected in >80% of CF samples, their percentage abundance within 
each sample was estimated by the percentage exponentially modified Protein 
Abundance Index (% emPAI [25]) using MS Excel. For proteins of consistently high 
abundance (>1% emPAI) in CF, % emPAIs were compared between the CF and 
control cohorts (Mann-Whitney U test). 
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Bivariate Spearman correlation analysis and univariate analysis were performed to 
identify proteins whose % emPAIs correlated with FEV1 % predicted and to identify 
independent factors. A Benjamini-Hochberg multiple comparisons adjustment was 
performed for the correlation analysis (MS Excel) to control the false discovery rate 
at <0.05. For each of the proteins correlating negatively with FEV1, paired T-tests 
and Wilcoxon signed-ranks tests were performed to compare the relative abundance 
(sample:reference) of matched CF pre-treatment and <24h post-treatment samples 
to identify differential abundances associated with antibiotic treatment of 
exacerbation. Again, the false discovery rate was controlled at <0.05 by a Benjamini-
Hochberg multiple comparisons adjustment. 
 
RESULTS  
Core signature proteome in CF cohort 
In accordance with inclusion criteria, the CF cohort comprised adults with CF who 
were chronically infected with P. aeruginosa. The cohort’s variation in % FEV1 
predicted (26-102%) and collection of 3 sputum samples from each individual 
(covering clinical stability, exacerbation and following antibiotic treatment of 
exacerbation) prevented proteome bias towards any particular clinical status within 
this population. In total, 2210 human proteins were detected including 119 which 
were common to all 48 samples, including those from healthy controls. A further 38 
proteins were detected in all samples belonging to only one cohort suggesting low 
abundance or absence in the other cohort, although differential abundance between 
the two cohorts cannot be proven statistically. Twenty-one proteins were detected 
only in the CF cohort and 17 proteins were detected only in the control cohort. Table 
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E3 in the online data supplement records all proteins detected in all the samples 
belonging to at least one cohort.  
The heatmap in Figure 1, which clusters individual sputum samples according to 
relative abundance levels (sample:reference) of consistently detected proteins, 
shows that CF and control samples largely cluster separately. The two exceptions, 
CF3.2 and CF4.2 (marked with an arrow in Figure 1), are CF samples collected just 
after completion of antibiotic treatment for a pulmonary exacerbation.  
IPA Canonical Pathways in CF and control cohorts 
The 136 proteins detected in all control samples and the 140 proteins detected in all 
CF samples were treated as consensus core proteomes for the two cohorts. 
Qualitative individual analysis of these proteomes was performed by Ingenuity 
Pathway Analysis (IPA) to determine Canonical Pathways predicted by IPA as active 
in each cohort. Figure 2 shows the top 5 Pathways predicted in the control proteome 
and all Canonical Pathways predicted by to have a >5-fold increase in p-value in the 
CF proteome compared to the control proteome, indicating likely up-regulation in CF. 
Those predicted as most up-regulated in CF are involved in immune functions 
including neutrophil recruitment, rearrangement of the actin cytoskeleton, 
phagocytosis and T cell signaling.  
IPA Bio Function analysis of the CF differential proteome  
Comparison of relative abundance levels (sample:reference) between the two 
cohorts (36 CF samples versus 12 control samples) was performed for the 119 
proteins detected in all samples in order to identify cohort differences. 54 proteins 
were found to be less abundant and 36 more abundant in the CF versus control 
cohort (independent samples T-tests & Mann Whitney U tests, p<0.05; Table E3, 
online data supplement). Abundance ratios (CF:control) for all differentially abundant 
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proteins were included for IPA Bio Function analysis irrespective of the degree of 
difference. Table E4 (online supplement) records the Bio Functions predicted to be 
differentially expressed (Fisher’s Exact Test, p<0.05) in CF with Regulation z-scores 
>1 or <-1 (IPA Regulation z-score algorithm, p<0.05), and those predicted with a 
higher confidence level (p<0.0005), but with a less noteworthy or absent Regulation 
z-score (shaded rows).  
Inflammatory Response, Cellular Movement, Cell Death, Cellular Growth and 
Proliferation, and Free Radical Scavenging were predicted by IPA as most altered in 
CF compared to the control cohort, with regard to the extent of regulation 
(Regulation z-score). This is largely supported by the data in Table E5 (online data 
supplement), which records Gene Ontology (GO) biological process classifications 
for the 38 proteins detected consistently in only one cohort, and the 6 proteins 
identified by Mann-Whitney U test as showing differential abundance between the 
two cohorts.  
High abundance proteins in CF sputum cells 
As high abundance proteins have greater potential for directly impacting the lung 
environment, we identified proteins that were consistently detected at high 
abundance per sample in the CF cohort and determined if their abundance levels per 
sample differed significantly from those of the control cohort. Six proteins were found 
to each comprise >1% of total human cellular protein per sample (% emPAI) in >80% 
of CF samples. Comparison of the % emPAIs for these proteins between CF and 
control cohorts detected increased abundance of all six in CF (independent samples 
Mann-Whitney U test, p<0.01). Their median±IQR % emPAIs are displayed in Figure 
4 along with the corresponding data for the control cohort. The Human Protein Atlas 
[26] identifies all as being either highly or moderately expressed in bone marrow 
Page 18 of 118European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 11 
 
hematopoietic cells (50% of which are myelopoietic cells) and all except cathepsin G 
as moderately or lowly expressed in lung macrophages. No statistically significant 
difference in relative abundance level (sample:reference) for these 6 proteins was 
detected when comparing paired CF pulmonary exacerbation samples before and 
<24h after antibiotic treatment (Wilcoxon signed-ranks test, p<0.05). 
Sputum cellular proteins correlate with lung function  
In order to identify any associations between specific proteins and lung function, the 
relative abundance levels (sample:reference) of the 337 proteins detected in >80% 
CF samples were tested for correlation with lung function as indicated by FEV1 % 
predicted. Negative correlations (Bivariate Spearman correlation analysis, p<0.01; 
false discovery rate <0.05) were identified for the 17 proteins listed in Table 2, 
implicating them as potential biomarkers of CF lung disease. Positive correlations 
were also identified, but as the focus of this analysis was to identify potentially 
injurious proteins only the negative correlations are presented here. Alpha-1-
antitrypsin and olfactomedin-4 were independent factors for FEV1 % predicted 
(univariate analysis, p<0.01).  
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UniProt 
Accession 
Description Gene name 
Spearman 
correlation 
(FEV1) 
Signif. 
(p-value) 
CF 
pre-
/post-
abx 
D3DSM0 Integrin beta-2 * ITGB2 -.751 0.00000 1.114 
P80723 Brain acid soluble protein 1 * BASP1 -.732 0.00000 1.343 
P02675 Fibrinogen beta chain ** FGB -.732 0.00000 1.690 
P01009 Alpha-1-antitrypsin SERPINA1 -.674 0.00001  
P30048 Thioredoxin-dependent peroxide 
reductase, mitochondrial 
PRDX3 -.646 0.00012 
 
J3QLC9 Haptoglobin * HP -.617 0.00028 1.288 
P08246 Neutrophil elastase ELANE -.608 0.00036  
Q08722 Leukocyte surface antigen CD47 
* 
CD47 -.608 0.00037 
1.115 
Q6UX06 Olfactomedin-4 ** OLFM4 -.601 0.00011 1.620 
P15144 Aminopeptidase N ANPEP -.540 0.00067  
F8VV56 CD63 antigen * CD63 -.586 0.00068 1.338 
C9JNR4 Transforming protein RhoA  RHOA -.578 0.00082 1.354 
P01023 Alpha-2-macroglobulin A2M -.543 0.00192  
O95498 Vanin 2 * VNN2 -.540 0.00205 1.475 
O94804 Serine/threonine-protein kinase 
10 
STK10 -.535 0.00233 
 
E7ER45 Maltase-glucoamylase, intestinal 
** 
MGAM -.523 0.00106 
1.314 
P08473 Neprilysin MME -.511 0.00146  
 
Table 2: Correlation between relative abundance level (sample:reference) and lung 
function (FEV1 % predicted) for proteins present in >80% CF samples at false 
discovery rate <0.05. * and ** indicate proteins with significantly different abundance 
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levels (p<0.05 and p<0.01, respectively) in the CF cohort when comparing matched 
pre-antibiotic and <24h post-antibiotic treatment samples. Median ratios (pre- 
treatment : <24h post-treatment) are recorded in the final column. 
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Longitudinal analysis of antibiotic treatment of CF exacerbation  
Figure E1 (online data supplement) shows that total protein yield (mg per g sputum) 
consistently decreased for each CF participant following antibiotic treatment of 
exacerbation and that follow-up samples collected during clinical stability more 
closely resembled pre-treatment samples with respect to yield. Individual proteins 
identified as correlating negatively with FEV1 % predicted (n=17) or consistently at 
high abundance in CF (n=6) were analysed to compare the relative abundance 
(sample:reference) of matched CF pre-treatment and <24h post-treatment samples. 
As shown in Table 2, paired samples T-tests (including Benjamini-Hochberg multiple 
comparisons adjustment of false discovery rate adjustment to <0.05) identified 9 
proteins with decreased abundance (p<0.05) following treatment of pulmonary 
exacerbation. Figure 1 shows that for 7 of the 12 individuals with CF, samples 
collected during clinical stability (labelled “.3”) clustered more closely with the 
matched pre-treatment sample (“.1”) than the post-treatment sample (“.2”). 
ELISA validation of candidate biomarkers 
As high abundance proteins (Figure 4) have greater potential for directly impacting 
the lung environment, we chose to validate myeloperoxidase and lactotransferrin as 
candidate biomarkers. Quantification of our existing samples by commercial ELISA 
confirmed their consistently higher abundance in CF compared to healthy control 
sputum cells (p<0.05, Mann Whitney U test, Figure E2 in the online supplement). 
Additionally, this demonstrated that commercial ELISAs are a practical method for 
follow-up validation of candidate biomarkers in a larger independent cohort. 
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DISCUSSION  
In order to further elucidate the mechanisms of CF-associated tissue damage in 
adults with chronic respiratory P. aeruginosa infection, this study has for the first time 
specifically investigated the global proteome and functional activity of the combined 
population of cells present in CF sputum. As such, it uniquely studies the protein 
abundance of cells in vivo, thereby taking into account both their natural frequency in 
the sputum cell population and the effects of intercellular interactions. Thus, it 
delivers a high degree of clinical relevance to our findings. Moreover, to accurately 
characterise a consistent CF phenotype for adults chronically infected with P. 
aeruginosa and avoid bias due to patient individuality, we considered only those 
proteins detected in all samples within the CF and healthy control cohorts. Thus, our 
study is more stringent than previously published proteomic studies that either 
included proteins detected at high frequency in at least one sample [18] or used 
pooled samples [14-16]. 
In agreement with previous investigations of CF sputum or BAL [14, 15, 17, 18], we 
found the CF proteome to be largely distinct from that of the control cohort. IPA 
predicted that Canonical Pathways which affect or involve actin cytoskeleton 
rearrangement directed by the Rho family small GTPases, including RhoA, Rac1 and 
Cdc42 were over-represented in the CF samples. Thus, our in vivo data confirms 
previous in vitro observations linking CFTR deficiency with increased RhoA 
expression [27, 28]. This may be significant for CF lung health as impaired 
efferocytosis (phagocytosis of apoptotic cells) [29] and reduced expression of iNOS 
[28] resulting from CFTR deficiency have been reported as mediated by RhoA up-
regulation. 
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Similarly to previous proteomics studies of cell-free CF sputum/BAL, GO and IPA Bio 
Function analyses identified up-regulation of the immune and inflammatory response 
[14-18]. In particular, we found increased immune cell movement and activation, and 
generation of reactive oxygen species. These observations fit with existing 
knowledge about the CF phenotype which is typified by chronic inflammation and 
neutrophilia. Interestingly, an IPA predicted network identified lipopolysaccharide as 
a likely trigger of inflammation. Cell death, growth and proliferation were also 
predicted as dysregulated in CF, in such a way that both death and proliferation of 
immune cells were decreased, while both were increased in non-immune cells. 
These observations further support the growing understanding of the CF phenotype. 
Tissue damage and cell death is rampant, while excessive proliferation of respiratory 
epithelial cells leading to squamous cell metaplasia and dysplasia is common in CF 
[30, 31]. Delayed neutrophil apoptosis and clearance is thought to contribute to 
chronic inflammation [2] and our study detected CF-associated differential 
abundance of matrix metalloproteinase 8, annexin I and nicotinamide 
phosphoribosyltransferase, which have been implicated in delayed apoptosis and 
clearing of inflammatory and immune cells in vitro [32] and in vivo [33, 34].  
Compositional breakdown analysis of sample proteomes found S100-A9, the histone 
H2B family, lactotransferrin, histone H4, cathepsin G and myeloperoxidase to be 
consistently present in high abundance in CF and to each be significantly more 
abundant in the CF cohort than the control cohort. Importantly, all six proteins are 
known constituents of neutrophil extracellular trap (NET) structures, the release of 
which by neutrophils exerts antimicrobial activity through the degradation of virulence 
factors, bacterial killing and antifungal activity [35-37].  
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As our study focused on sputum cellular proteins we did not look specifically for NET 
structures, which are extracellular, and therefore do not know if they were present. 
However, NETs have been found previously in the CF airways fluid and the 
abundance of free DNA that is characteristic of NETs correlated with obstructive lung 
function [38]. As well as killing microbes, NETs have been found to directly induce 
human alveolar epithelial and endothelial cell death, with the predominant cytotoxic 
effect being attributed to histones and myeloperoxidase [39].   
Individually, these six high abundance proteins may also have significance for CF 
lung pathology and several have previously been reported as up-regulated in CF 
sputum and/or BALF [14, 15, 18]. Importantly, differential abundance of 
myeloperoxidase in CF sputum fluid has been correlated with FEV1 % predicted [17], 
and myeloperoxidase and calgranulin B have been identified in sputum fluid as CF-
associated autoantigens [16]. Cathepsin G has been implicated in degradation of 
surfactant protein A, so reducing the innate pulmonary antimicrobial defence [40], 
while S100-A9 has been shown to induce MUC5AC production in human bronchial 
epithelial cells cultured in vitro, suggesting a potential contribution to pathological 
mucin hyperproduction in vivo [41]. In a study investigating trauma-induced lung 
injury, Abrams et al. reported that histones induced NET formation and 
myeloperoxidase release in vitro, while histone infusion in mouse models resulted in 
lung structural damage and neutrophil congestion [42]. Additionally, extracellular 
histones H4 and H3.3 have been implicated in asthma-related inflammation and 
remodeling, and in chronic obstructive pulmonary disease (COPD), respectively [43, 
44]. Consequently, our consistent detection of these proteins in such high 
abundance in the sputum cellular fraction identifies a potential risk to lung health, 
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either through their active secretion and NET formation or following passive release 
into the sputum fluid via cell death. 
A number of proteins detected consistently in CF sputum correlated negatively with 
lung function measured as FEV1 % predicted. Their biological/clinical relevance and 
potential for causing injury are discussed more fully in the online supplement. 
Longitudinal analysis of patient-matched CF samples showed differential 
abundances for 10 out of these 17 proteins in the CF cohort following intravenous 
antibiotic treatment of a pulmonary exacerbation. Interestingly, all the changes in 
abundance resulted in levels closer to those in the control cohort. Previously, Sloane 
et al [17] observed that for 4/13 adults with CF, their cell-free sputum proteome 
profiles moved closer to those of healthy controls following antibiotic treatment of an 
exacerbation. However, the latter observations were made by comparison of 2-D gel 
images rather than implicating and identifying particular proteins. We also found that, 
although sputum total protein yield decreased in the CF cohort by completion of 
antibiotic treatment, it had reverted to pre-treatment levels by the clinically stable 
follow-up time point. This suggests that proteomic changes associated with antibiotic 
treatment may be temporary. 
Overall, the proteins detected as negatively correlating with FEV1 suggest that the 
degree of inflammation, neutrophil influx, protease activity and airway remodeling 
may all contribute to defining lung function. Alpha-1-antitrypsin and olfactomedin-4 
were identified as independent factors negatively correlating with FEV1  although this 
does not demonstrate causation of harm.  Acute inflammation-associated protein 
alpha-1-antitrypsin has previously been identified as a biomarker of pulmonary 
disease in CF which can be predictive of response to treatment and prognosis [45]. 
As an inhibitor of neutrophil serine proteases, which contribute significantly to lung 
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destruction in CF, its negative correlation with lung function might seem surprising. 
However, previous studies observed that plasma deficiencies during inflammation 
were associated with less severe lung disease in CF [46]. No association between 
olfactomedin-4 and CF lung health has previously been reported. However, 
olfactomedin-4 has been shown to down-regulate proinflammatory responses to 
bacterial infection and reduce bacterial killing mediated by granule serine 
proteinases [47, 48], which could have the potential to negatively affect lung health.  
There are a number of limitations to our study. As is typical for untargeted 
exploratory proteomic studies, we used highly sensitive shotgun technologies to 
obtain quantitative, high proteome coverage analysis of sputum cells as a novel 
target. The trade-off for such in-depth analysis is a relatively low sample size. Given 
the sample numbers practicable, we maximised power by restricting the study to 
adults with CF chronically infected with P. aeruginosa, who experienced pulmonary 
exacerbation requiring hospitalization for treatment with intravenous antibiotics. 
While CF sputum proteome responses to other microbial infections may vary, we 
considered this cohort most informative as 57% of the adult CF population is 
chronically infected with P. aeruginosa [49]. As this study investigated only adults the 
findings cannot be extended to children or individuals not chronically infected with P 
aeruginosa. Although proteins reported as potentially damaging were detected as 
consistently abundant or correlating negatively with lung function in our study, this is 
not proof of causation of lung injury. Additionally, the limited sample size requires 
that any potential significance as biomarkers either of lung function or disease 
severity warrants validation in a larger independent cohort. As an intial stage in this 
validation process we used commercial ELISAs to confirm findings in our existing 
cohort for myeloperoxidase and lactotransferrin. Both proteins were considered as 
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candidate biomarkers due to their consistently high abundance in CF sputum, 
increased abundance in the CF compared to the control cohort and previous 
associations in the literature with potential for lung damage. Thus, we demonstrated 
that commercial ELISAs are a practical method for follow-up validation in an 
independent cohort. However, while cohort size and characteristics limit the scope of 
our study conclusions, the findings are of exploratory interest and may have future 
clinical value within a defined commonly encountered CF cohort.  Moreover, the 
investigation of all types of cells in the proportions occurring naturally in sputum is 
novel and the approach adopted in our study could be informative for other 
respiratory conditions. 
In summary, within the cohort studied, i.e. adults with chronic P. aeruginosa 
infection, we have detected a distinct signature for the CF sputum cellular proteome, 
and have used pathway and functional analyses to predict its potential clinical 
impact.  In particular, our data highlight the prevalence and predominance of proteins 
that can be associated with NET structures and have been reported as linked to 
tissue damage. Additionally, we identified a number of proteins that correlate 
negatively with lung function, many of which have previously been associated with 
lung injury. Overall, these findings expand the current understanding of the 
mechanisms behind P. aeruginosa associated CF lung disease in adults and identify 
sputum cell proteins as candidate biomarkers for disease status, prognostic 
indicators or as stratification parameters for treatment prescription. 
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Figure 1: Distribution and relative abundance of human proteins detected in sputum 
samples collected from CF and healthy control cohorts. A. shows that 119 proteins 
were found in all 48 samples, i.e. both CF and control, while a further 21 proteins 
were found exclusively in all CF samples and 17 proteins exclusively in all control 
samples. B. shows hierarchical clustering (using Euclidean distance dissimilarity and 
McQuitty’s linkage criteria) of individual sputum samples according to the relative 
abundance levels for all 119 consistently detected proteins. CF and control samples 
largely cluster separately with the only exceptions being 2 CF samples (marked with 
black arrows) collected after antibiotic treatment for pulmonary exacerbation. The 
scale is a log2 ratio of relative abundance.   
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Figure 2: Differential activity of Canonical Pathways in consensus CF and control 
proteomes.  Based on the set of proteins detected in all samples within a cohort, 
Ingenuity Pathway Analysis software applied Fisher’s Exact Test to predict the 
Canonical Pathways likely to be active within that cohort (p<0.05). The top 5 
pathways predicted in the control cohort concern general metabolism, clatherin-
mediated endocytosis signaling and mitochondrial dysfunction and these were 
detected with approximately equal probabilities in both cohorts. Pathways where 
there is a >5-fold increase in p-value in the CF proteome compared to the control 
proteome, indicating likely up-regulation in CF are involved in immune functions 
including neutrophil recruitment, rearrangement of the actin cytoskeleton, 
phagocytosis and T cell signaling.  
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Figure 3: Ingenuity Pathway Analysis predicted network for proteins detected in CF 
involved in Inflammatory Response and Cell Movement Bio Functions. The intensity 
of red or green shading indicates the degree of increased or decreased abundance 
in CF relative to healthy controls, respectively. A red outline with no internal shading 
indicates that the protein was detected exclusively in the CF cohort. The network 
identifies lipopolysaccharide (LPS) as a likely inflammatory trigger. 
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Figure 4: Percentage abundance estimates (% emPAI median ± IQR) for proteins 
comprising >1% of total human proteins in >80% of CF samples. Human Protein 
Atlas (26) annotations for protein expression in terms of tissue location and localised 
abundance are recorded. H, M and L indicate high, medium and low protein 
expression. All proteins are either highly or moderately expressed in bone marrow 
hematopoietic cells, 50% of which are myelopoietic cells, and all except cathepsin G 
are moderately or lowly expressed in lung macrophages. 
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METHODS 
Extraction of sputum cellular proteins 
All work was carried out at 4°C and using prechilled buffers. Approximately 1g of 
mucus plug was separated from each sputum sample and mixed with 9 ml sterile 
phosphate buffered saline pH 7.4 (PBS) containing Roche Complete Mini protease 
inhibitor cocktail (PIC). The mixture was homogenised thoroughly by repeat syringing 
(no needle) and cells pelleted by centrifugation for 10 min at 4,000 x g. The cells 
were washed twice more in 10 ml PBS+PIC and strained through a 70 µm nylon cell 
strainer (BD Biosciences) to remove any remaining cell clumps. The cells were 
pelleted once more to remove all supernatant before protein extraction. Cell pellets 
were resuspended in 0.2 - 3.0 ml lysis buffer (10 mM HEPES, 0.5 mM EDTA, 1% v/v 
Nonidet P 40, 4% w/v SDS, pH 8.0) depending on pellet size and Sigma protease 
inhibitor cocktail added at 10 µl per 1 ml as directed. After thorough homogenisation 
by vortexing and repeat passage through an 18-gauge needle, the mixtures were 
subjected to 5 freeze-thaw cycles and water bath sonication to ensure lysis. 
Insoluble cell debris was removed by centrifugation at 14,000 x g and the soluble 
protein supernatants were stored at -80°C.  
Protein digestion and iTRAQ labelling 
Protein digestion and iTRAQ labelling were performed as described previously (1). 
Protein concentrations were determined by BCA Protein Assay (Pierce). 
ProteaseMax (Promega) made up in 50 mM triethylammonium bicarbonate (TEAB) 
was added to a final concentration of 0.1% to 70 µg of each protein sample. The 
samples were reduced with 5 mM tris-(2-carboxyethyl) phosphine at 55°C for 20 min 
and alkylated with 10 mM methyl methanethiosulphonate at room temperature for 20 
min. Following methanol/chloroform precipitation for 60 min at 4°C, protein pellets 
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were resuspended in 50 mM TEAB, 0.1% Proteasemax and trypsin digested 
overnight at 37°C. The tryptic peptides were dried to <5 µl by vacuum centrifugation 
and diluted with 500 mM TEAB to a final volume of 30 µl, before acidification with 
trifluoroacetic acid and labelling with 8plex iTRAQ Reagents (AB Sciex) according to 
kit instructions. 
MudPIT 
Six test samples and a reference sample were mixed for simultaneous analysis by 
2D liquid chromatography MudPIT, using a two-dimensional Vented Column Setup 
with a Proxeon nano-flow high-performance liquid pump as described previously (1). 
Eight MudPIT runs were performed in total and the samples combined per run are 
recorded in Table E6. Each salt step was eluted at 3.5 µl/min on an analytical 
column (100 µm internal diameter packed with 12 cm of 5 µm Aqua C18) on line with 
an LTQ Orbitrap Velos (Thermo Electron). Data were acquired in profile mode using 
the following parameters: for full-scan Fourier transform mass spectrometry, 
resolution = 60,000, m/z = 380–1,700 and the 10 most intense ions were fragmented 
with higher-collision dissociation at a normalised collision energy of 40% and an 
activation time of 0.1. Minimum threshold signal was at 5,000 and isolation width at 
1.2. Dynamic exclusion settings were repeat count 1, repeat duration of 30, 
exclusion list size 500, exclusion duration 60 and exclusion mass width 10 p.p.m. 
Protein identification 
Peaklists were generated by Mascot Distiller (Matrix science; version 2.3). Protein 
identification was performed by the Mascot search engine version 2.3 against the 
UniProt human database 2016 (92,179 sequences) plus NCBI non-redundant 
database (2016), taxonomy P. aeruginosa (634,627 sequences) with a precursor 
mass tolerance of 20 p.p.m., with iTRAQ8plex (N-terminal) and iTRAQ8plex (lysine) 
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as fixed modifications and oxidation (methionine) and deamidated (asparagine & 
lysine) as variable modifications. Trypsin was set as the cleavage enzyme and one 
missed cleavage was allowed. A mass tolerance of 0.3 Da was set for fragment ions. 
Mascot Percolator was used to re-score the results to false discovery rates of 0.74-
1.16% for protein identification. Protein identifications with a MOWSE score less than 
65 were rejected. Protein-level iTRAQ ratios were calculated as intensity weighted, 
using only peptides with expectation values less than 0.05. Global ratio normalization 
was performed using intensity summation, with no outlier rejection.  
Enzyme-linked Immunosorbent assay (ELISA) 
In order to validate myeloperoxidase and lactotransferrin as high abundance proteins 
in the CF cohort compared to control cohort and to demonstrate that commercial 
ELISAs are a practical method for validation of candidate biomarkers, both proteins 
were quantified in each sample by ELISA (ab119605 and ab108882 respectively, 
Abcam, Cambridge, UK) according to the manufacturer’s instructions. Figure E2 
shows the median±IQR % abundance for each candidate biomarker along with the 
corresponding data for the control cohort.   
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Western immunoblot 
Western immunoblot was used to further confirm the mass spectrometry 
identification and quantification data (Figure E3). Patient sample protein 
concentrations were assessed by BCA assay (Thermo Scientific Inc., Rockford, 
USA). 25 µg of protein was loaded per lane on 4-20% TGXTM gels and transferred to 
0.45 µm PVDF membrane (Millipore Corproration, Massachusetts, USA) with a 
CriterionTM mini gel tank and blot module, associated buffers and power supply, 
according to the manufacturer’s guidelines (Bio-rad Laboratories Inc., Hercules, 
USA). Nonspecific binding was blocked overnight at 4 °C using 5% non-fat milk in 
PBS with 0.05% Tween 20 (PBST) (Sigma-Aldrich Company Ltd., Gillingham, UK). 
Primary antibodies against azurocidin, heatshock protein beta 1 and cytokeratin 
(Abcam Ltd, Cambridge, UK) were incubated with blotted membranes at a diluted in 
PBST, for 1 h at room temperature. Membranes were washed 3 times (5 min each) 
with PBST and incubated in secondary anti-IgG horseradish peroxidase diluted in 
PBST (Promega Inc., Madison, USA), for 1 h at room temperature. After a further 6 
washes, bands were visualized using Supersignal West Pico chemiluminescent 
substrate (Thermo Scientific Inc., Rockford, USA), imaged with a Autochemi CCD 
camera and analysed with Labworks software version 4.0.0.8 (UVP Ltd., Cambridge, 
UK). 
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DISCUSSION 
A number of proteins detected consistently in CF sputum correlated negatively with 
lung function measured as FEV1 % predicted. Their biological/clinical relevance and 
potential for causing injury are discussed below. Interestingly, 9 out of these 15 
proteins also showed differential abundance in the CF cohort following intravenous 
antibiotic treatment of a pulmonary exacerbation, with the changes in abundance 
bringing them closer to levels in the control cohort. 
Acute inflammation-associated proteins alpha-1-antitrypsin, haptoglobin, fibrinogen 
and alpha-2-macroglobulin have previously been identified as serum biomarkers of 
pulmonary disease including CF and COPD and can be predictive of response to 
treatment and prognosis (2-6). The presence of these proteins in the lungs has 
traditionally been thought to be due to plasma leakage. However, haptoglobin and 
fibrinogen may also be synthesized in the lungs in response to inflammation and 
injury, and may exert roles in immunity and repair mechanisms (7, 8). Alpha-1-
antitrypsin is an inhibitor of neutrophil serine proteases, including elastase, which 
contribute significantly to lung destruction in CF, and therefore its negative 
correlation with lung function might seem surprising. However, previous studies 
observed that plasma deficiencies during inflammation were associated with less 
severe lung disease in CF (9, 10). Fibrinogen has been shown to increase mucin 
production in airway epithelial cells (11), which could contribute to the CF 
hypersecretory phenotype. 
Three proteins associated with the migration of neutrophils, lymphocytes and 
alveolar monocytes – integrin beta 2, vanin-2 and serine/threonine-protein kinase 10 
(12-14) – correlated negatively with lung function.  This correlation could be due to 
either the negative impact of these cells as part of an overactive immune system or 
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poor lung health stimulating an increased influx of immune cells. In accordance with 
the predicted neutrophil influx in CF, four granule proteins – neutrophil elastase, 
olfactomedin-4, CD63 antigen and maltase-glucoamylase – were also found to 
correlate negatively with lung function. Neutrophil elastase exerts antimicrobial 
activity and therefore might be expected to promote lung health. However, CF-
associated accumulation of neutrophil elastase can be damaging to lung tissue (15-
17) and sputum measurements have previously been shown to predict the rate of 
FEV1 decline in children with CF (18), while higher levels of neutrophil elastase 
following antibiotic treatment of an exacerbation have been associated with an 
increased risk of subsequent exacerbation (19). Additionally, serum levels of 
elastase/alpha-1-antitrypsin complex have been found to predict response to 
treatment of chronic P. aeruginosa colonisation (3). In contrast, olfactomedin-4 has 
been shown to down-regulate proinflammatory responses to bacterial infection and 
reduce bacterial killing mediated by granule serine proteinases (20, 21), which would 
be expected to negatively affect lung health. Additionally, olfactomedin-4 has 
recently been identified as a novel target autoantigen for antineutrophil cytoplasmic 
antibodies (ANCA), although both cases reported were for people without CF (22).  
Neprilysin cleaves inflammatory peptides and has been proposed as protective 
against hypoxia- and smoke-related pulmonary vascular remodeling in COPD (23, 
24), while thioredoxin-dependent peroxidase reductase has been implicated as an 
important scavenger of reactive oxygen species during LPS-induced oxidative stress 
and gene knockout mice showed increased lung inflammation (25). Although both 
correlated negatively with lung function, there is no published data suggesting their 
effects can be harmful. Thus, it is likely that observed levels signify a response to 
inflammation rather than a cause. BASP1 is strongly expressed in ciliated respiratory 
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cells (26) and its detection in sputum cells is likely indicative of significant 
dislodgement of these cells and injury to the respiratory tract that would be expect to 
hinder mucus clearance. Additionally, increased BASP1 expression has been linked 
to apoptosis of human tubular epithelial cells and in diabetic nephropathy (27).  
Finally, levels of RhoA also correlated negatively with lung function. As already 
discussed, RhoA is involved in the regulation of many activities relating to 
inflammatory and immune response repair such as phagocytosis, cell migration and 
wound closure. In part its negative correlation with lung function may reflect the 
degree of injury, but also its promotion of neutrophil influx may incur a mechanism 
for tissue damage.  
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Sample type CF phenotype/observation Refs 
human nasal 
epithelial cells 
reduced expression of the anti-inflammatory protein annexin 
A1 in CF 
(28) 
human nasal 
epithelial cells 
differential expression of proteins related to chronic 
inflammation, oxidative stress, cytoskeleton proteins and 
mitochondrial proteins  
(29) 
mouse airway 
epithelial cells 
reduced expression of carbonyl reductase (prostaglandin 
metabolism) and a more pronounced down-regulation of two 
key enzymes of retinoic acid metabolism after injury  
(30) 
human nasal 
epithelial cells  
multiple-biomarker signature patterns for CF  (31) 
human 
bronchial 
epithelial cell 
line 
differences in glycolytic and gluconeogenic pathways, 
unfolded protein responses and a signaling pathway involved 
in cellular calcium homeostasis  
(32) 
human 
bronchial 
epithelial cell 
line 
differential regulation of protein folding and degradation as 
well as differential expression of other proteins likely to relate 
to CF pathology 
(33) 
human 
bronchial 
epithelial cell 
line 
differential regulation of COP9 signalosome, cellular response 
to interleukin-4, response to salt stress, protein binding 
involved in protein folding, cell redox homeostasis & actin 
cytoskeleton 
(34) 
human nasal 
epithelial cells 
impairment of pathways relating to metabolism, G protein 
process, inflammation and oxidative stress response, protein 
folding, proteolysis and structural proteins 
(35) 
human differential enrichment/depletion of innate immunity, (36) 
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bronchial 
epithelial cell 
line secretions 
cytoskeleton/extracellular matrix organization & 
protease/antiprotease activity;  oxidative & classical 
complement pathways altered in vivo were not altered in vitro 
cell-free 
sputum fluid or 
BALF 
distinct CF protein profiles observed  (37-39) 
cell-free BALF less complete cohort clustering for young children with CF 
than for non-CF children with active lung disease 
(40) 
cell-free 
sputum fluid 
2-D gel electrophoresis protein profiles from CF adults 
approached a “healthy” profile after hospitalized treatment  
(38) 
cell-free 
sputum fluid or 
BALF 
increased immune response, proteolytic activity and 
dysregulation of complement in CF  
(38, 39) 
cell-free 
sputum fluid or 
BALF 
identification of CF-associated inflammatory biomarkers and 
autoantigens, including myeloperoxidase, interleukin 8 and 
calgranulins A, B & C  
(37, 38, 
41) 
 
Table E1: Summary of previous proteomic studies of the CF airways. 
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IV abx for treatment of 
current PEx 
long-term oral 
abx 
oral abx 
(previous 30 
days) 
inhaled abx 
(previous 30 
days) 
CF1 
meropenem & 
tobramycin azithromycin - 
tobramycin & 
colistin 
CF2 ceftazidime & tobramycin - - 
tobramycin & 
colistin 
CF3 cefuroxime & colistin azithromycin - tobramycin 
CF4 
piperacillin/ 
tazobactam & tobramycin azithromycin - colistin 
CF5 
piperacillin/ 
tazobactam, aztreonam 
& chlorphenamine - - 
tobramycin & 
colistin 
CF6 
piperacillin/ 
tazobactam & tobramycin azithromycin ciprofloxacin colistin 
CF7 tobramycin & temocillin azithromycin - 
tobramycin & 
colistin 
CF11 
piperacillin/ 
tazobactam & tobramycin - - tobramycin 
CF12 aztreonam & tobramycin azithromycin - 
tobramycin & 
colistin 
CF13 aztreonam & tobramycin azithromycin - colistin 
CF15 aztreonam & tobramycin azithromycin ciprofloxacin colistin 
CF16 
tobramycin, ceftazidime 
& colistin azithromycin N tobramycin 
 
Table E2: Treatment regimens of the CF cohort.  
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UniProt 
Accession 
Gene 
Name 
Description 
Log2 mean 
CF/control 
Signif 
(p) 
Q14764 MVP  Major vault protein 
Reduced in 
CF 
0.002 
P28676 GCA  Grancalcin 2.347 0.000 
P01833 PIGR  Polymeric immunoglobulin receptor -1.467 0.000 
O15144 ARPC2 Actin-related protein 2/3 complex subunit 2 - n.s. 
P52907 CAPZA1  F-actin-capping protein subunit alpha-1 -1.060 0.000 
P05023 ATP1A1 
Sodium/potassium-transporting ATPase 
subunit alpha-1 
- n.s. 
P05091 ALDH2  Aldehyde dehydrogenase, mitochondrial -1.944 0.000 
Q9HD89 RETN  Resistin 1.968 0.000 
P05141 SLC25A5 ADP/ATP translocase 2 - n.s. 
P38606 ATP6V1A  V-type proton ATPase catalytic subunit A -1.586 0.000 
P21281 ATP6V1B2  
V-type proton ATPase subunit B, brain 
isoform 
-1.153 0.000 
Q01518 CAP1  
Isoform 1 of Adenylyl cyclase-associated 
protein 1 
-0.580 0.008 
Q9UM07 PADI4 Protein-arginine deiminase type-4 - n.s. 
Q9Y6N5 SQRDL  
Sulfide:quinone oxidoreductase, 
mitochondrial 
-0.612 0.002 
P13646 KRT13  Isoform 1 of Keratin, type I cytoskeletal 13 -3.704 0.000 
P13667 PDIA4  Protein disulfide-isomerase A4 -0.798 0.000 
P13796 LCP1  Plastin-2 0.362 0.049 
P07237 P4HB  Protein disulfide-isomerase 0.302 0.027 
P48735 IDH2 
Isocitrate dehydrogenase [NADP], 
mitochondrial 
0.551 0.012 
P23368 ME2 
NAD-dependent malic enzyme, 
mitochondrial 
Increased 
in CF 
0.000 
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P07339 CTSD  Cathepsin D -2.120 0.000 
P07384 CAPN1  Calpain-1 catalytic subunit -0.864 0.001 
P23528 CFL1 Cofilin-1 - n.s. 
P41218 MNDA  Myeloid cell nuclear differentiation antigen 1.051 0.000 
P31943 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H - n.s. 
P15924 DSP  Isoform DPI of Desmoplakin -2.154 0.000 
Q15080 NCF4 Neutrophil cytosol factor 4 
Increased 
in CF 
0.000 
Q15149 PLEC  Plectin -1.452 0.000 
P09622 DLD  Dihydrolipoyl dehydrogenase, mitochondrial -0.930 0.000 
Q6P4A8 PLBD1 Phospholipase B-like 1 - n.s. 
P51149 RAB7A  Ras-related protein Rab-7a -0.379 0.022 
P51159 RAB27A Ras-related protein Rab-27A 1.698 0.000 
P00367 GLUD1  Glutamate dehydrogenase 1, mitochondrial -1.568 0.000 
P00403 MT-CO2  Cytochrome c oxidase subunit 2 -0.759 0.006 
P00450 CP  Ceruloplasmin -0.662 0.016 
P43353 ALDH3B1  
Aldehyde dehydrogenase family 3 member 
B1 
-0.878 0.001 
P00505 GOT2  Aspartate aminotransferase, mitochondrial -1.137 0.000 
P43490 NAMPT  Nicotinamide phosphoribosyltransferase 0.797 0.000 
P61626 LYZ  Lysozyme C -0.548 0.002 
P35579 MYH9 Myosin-9 - n.s. 
P27797 CALR Calreticulin - n.s. 
P27824 CANX Calnexin - n.s. 
P10606 COX5B 
Cytochrome c oxidase subunit 5B, 
mitochondrial 
- n.s. 
P10644 PRKAR1A  
cAMP-dependent protein kinase type I-
alpha regulatory subunit 
0.914 0.000 
Q92542 NCSTN Nicastrin - n.s. 
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P20160 AZU1  Azurocidin 1.693 0.000 
Q6UX06 OLFM4  Olfactomedin-4 1.636 0.000 
P55072 VCP  Transitional endoplasmic reticulum ATPase -1.079 0.000 
P55084 HADHB  
Trifunctional enzyme subunit beta, 
mitochondrial 
-1.211 0.000 
P12273 PIP  Prolactin-inducible protein -1.746 0.000 
Q08380 LGALS3BP  Galectin-3-binding protein -2.038 0.000 
O75131 CPNE3  Copine-3 1.068 0.000 
P30040 ERP29  Endoplasmic reticulum resident protein 29 1.499 0.000 
P12724 RNASE3 Eosinophil cationic protein 
Increased 
in CF 
0.001 
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 
Increased 
in CF 
0.004 
P04792 HSPB1  Heat shock protein beta-1 -3.468 0.000 
P04843 RPN1  
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 precursor 
-1.065 0.000 
P14314 PRKCSH Glucosidase 2 subunit beta - n.s. 
P14625 HSP90B1  Endoplasmin -0.391 0.009 
P40121 CAPG Macrophage-capping protein - n.s. 
O75955 FLOT1  Flotillin-1 0.782 0.001 
P30740 SERPINB1  Leukocyte elastase inhibitor 1.050 0.000 
P14780 MMP9 Matrix metalloproteinase-9 - n.s. 
P22894 MMP8  Neutrophil collagenase 1.777 0.000 
P08311 CTSG Cathepsin G 2.147 0.000 
P61158 ACTR3  Actin-related protein 3 -0.648 0.000 
O60234 GMFG  Glia maturation factor gamma 1.663 0.000 
P50395 GDI2 Rab GDP dissociation inhibitor beta - n.s. 
P40939 HADHA  
Trifunctional enzyme subunit alpha, 
mitochondrial 
-1.428 0.000 
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P00558 PGK1 Phosphoglycerate kinase 1 - n.s. 
P13639 EEF2  Elongation factor 2 -1.224 0.000 
P10599 TXN  Thioredoxin -1.289 0.000 
P07737 PFN1 Profilin-1 - n.s. 
P30038 ALDH4A1 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial 
- n.s. 
P04839 CYBB  Cytochrome b-245 heavy chain 1.197 0.000 
P09917 ALOX5 Arachidonate 5-lipoxygenase - n.s. 
P04083 ANXA1  Annexin A1 -1.957 0.000 
P52209 PGD 
6-phosphogluconate dehydrogenase, 
decarboxylating 
- n.s. 
P27105 STOM  
Erythrocyte band 7 integral membrane 
protein 
1.685 0.000 
P09211 GSTP1  Glutathione S-transferase P -0.741 0.000 
P15144 ANPEP  Aminopeptidase N 0.486 0.007 
Q8WUM4 PDCD6IP Programmed cell death 6-interacting protein - n.s. 
Q12913 PTPRJ  
Receptor-type tyrosine-protein 
phosphatase eta precursor 
0.621 0.006 
P40926 MDH2  Malate dehydrogenase, mitochondrial -1.000 0.000 
Q8TDL5 BPIFB1 BPI fold-containing family B member 1 -1.470 0.003 
Q14739 LBR Lamin-B receptor - n.s. 
P49913 CAMP  Cathelicidin antimicrobial peptide precursor 1.215 0.002 
Q8IX19 MCEMP1 Mast cell-expressed membrane protein 1 
Increased 
in CF 
0.000 
Q9Y2J8 PADI2  Protein-arginine deiminase type-2 0.915 0.005 
P39656 DDOST  
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
-0.909 0.001 
Q13576 IQGAP2  Ras GTPase-activating-like protein IQGAP2 0.546 0.001 
P80188 LCN2  Neutrophil gelatinase-associated lipocalin 1.806 0.000 
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Q15084 PDIA6 Protein disulfide-isomerase A6 -0.570 0.035 
P21333 FLNA  Isoform 2 of Filamin-A -0.897 0.000 
P50990 CCT8  T-complex protein 1 subunit theta -0.833 0.000 
P06576 ATP5B  ATP synthase subunit beta, mitochondrial -1.416 0.000 
A6NI72 NCF1B  Putative neutrophil cytosol factor 1B 
Increased 
in CF 
0.000 
P10909 CLU  Clusterin -2.856 0.000 
P69905 
HBA1 & 
HBA2 
Hemoglobin subunit alpha - n.s. 
P07355 ANXA2  Isoform 2 of Annexin A2 -2.744 0.000 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A - n.s. 
P25705 ATP5A1  ATP synthase subunit alpha, mitochondrial -0.751 0.010 
P62805 
HIST1H4F/
HIST1H4C;
HIST1H4A;
HIST1H4I;
HIST1H4B;
HIST2H4B;
HIST1H4L;
HIST1H4E;
HIST1H4D;
HIST1H4J;
HIST1H4K;
HIST1H4H;
HIST2H4A;
HIST4H4  
Histone H4 1.775 0.000 
Q14204 DYNC1H1  Cytoplasmic dynein 1 heavy chain 1 
Reduced in 
CF 
0.001 
P06733 ENO1  Alpha-enolase -0.694 0.002 
P04040 CAT  Catalase 1.108 0.000 
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P14618 PKM Pyruvate kinase PKM - n.s. 
P13489 RNH1  Ribonuclease inhibitor -0.549 0.001 
P01011 SERPINA3 Alpha-1-antichymotrypsin 0.548 0.048 
P01009 SERPINA1  Alpha-1-antitrypsin 1.036 0.001 
P29401 TKT Transketolase 0.955 0.000 
P22314 UBA1 Ubiquitin-like modifier-activating enzyme 1 - n.s. 
P37837 TALDO1  Transaldolase -0.581 0.019 
O75083 WDR1 WD repeat-containing protein 1 - n.s. 
P01024 C3  Complement C3 
Reduced in 
CF 
0.020 
Q14254 FLOT2 Flotillin-2 - n.s. 
P50995 ANXA11  Annexin A11 1.198 0.000 
Q5JTV8 TOR1AIP1  Torsin-1A-interacting protein 1 -0.511 0.001 
O43451 MGAM  Maltase-glucoamylase, intestinal 2.495 0.000 
P36222 CHI3L1 Chitinase-3-like protein 1 CF only n.a. 
P61160 ACTR2 Actin-related protein 2 CF only n.a. 
Q9H9B4 SFXN1 Sideroflexin-1 CF only n.a. 
P48595 
SERPINB1
0 
Serpin B10 CF only n.a. 
Q13043 STK4 Serine/threonine-protein kinase 4 CF only n.a. 
P15498 VAV1 Proto-oncogene vav CF only n.a. 
Q13636 RAB31 Ras-related protein Rab-31 CF only n.a. 
Q9H4M9 EHD1 EH domain-containing protein 1 CF only n.a. 
Q99829 CPNE1 Copine-1 CF only n.a. 
P20592 MX2 
Interferon-induced GTP-binding protein 
Mx2 
CF only n.a. 
P57737 CORO7 Coronin-7 CF only n.a. 
P34059 GALNS N-acetylgalactosamine-6-sulfatase CF only n.a. 
P26038 MSN Moesin CF only n.a. 
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P08473 MME Neprilysin CF only n.a. 
Q9P107 GMIP GEM-interacting protein CF only n.a. 
P07332 FES Tyrosine-protein kinase Fes/Fps CF only n.a. 
Q9NUQ9 FAM49B Protein FAM49B CF only n.a. 
P98171 ARHGAP4 Rho GTPase-activating protein 4 CF only n.a. 
Q86YV0 RASAL3 RAS protein activator like-3 CF only n.a. 
Q14005 IL16 Pro-interleukin-16 CF only n.a. 
P30153 PPP2R1A 
Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha isoform 
CF only n.a. 
P62834 RAP1A Ras-related protein Rap-1A control only n.a. 
Q07954 LRP1 
Prolow-density lipoprotein receptor-related 
protein 1 
control only n.a. 
P02786 TFRC Transferrin receptor protein 1 control only n.a. 
Q9NZM1 MYOF  
Myoferlin 
 
control only n.a. 
P10253 GAA Lysosomal alpha-glucosidase control only n.a. 
P07858 CTSB Cathepsin B control only n.a. 
Q5JXB2 UBE2NL 
Putative ubiquitin-conjugating enzyme E2 
N-like 
control only n.a. 
Q96TC7 RMDN3 
Regulator of microtubule dynamics protein 
3 
control only n.a. 
P13686 ACP5 
Tartrate-resistant acid phosphatase type 5 
 
control only n.a. 
Q5TD94 RSPH4A Radial spoke head protein 4 homolog A control only n.a. 
Q5RHP9 ERICH3 Glutamate-rich protein 3 control only n.a. 
P18124 RPL7 60S ribosomal protein L7  control only n.a. 
Q9NQ38 SPINK5 
Serine protease inhibitor Kazal-type 5 
 
control only n.a. 
Q8N392 ARHGAP1 Rho GTPase-activating protein 18 control only n.a. 
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8 
Q13838 DDX39B Spliceosome RNA helicase DDX39B control only n.a. 
P19013 KRT4  
Keratin, type II cytoskeletal 4 
 
control only n.a. 
O15031 PLXNB2  Plexin-B2 control only n.a. 
 
Table E3: Proteins detected in all 48 sputum samples or all samples belonging to at 
least one cohort. Where independent samples T-tests identified differential 
abundance between the cohorts (p<0.05) the log2 ratio of mean abundance levels 
and significance are recorded. Where Mann-Whitney U Tests identified differential 
abundance (p<0.05) increased or decreased abundance in CF is recorded along with 
significance. No significant difference in abundance between the cohorts is recorded 
as “-“. 
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Functions Category Bio Functions Annotation 
Confidence  
level  
(p-value) 
Regulation  
z-score 
Cell Death apoptosis of neutrophils 3.56E-09 -1.308 
Cell Death apoptosis of myeloid cells 6.85E-07 -1.108 
Cell Death killing of cells 6.31E-05 1.88 
Cell Death cell survival 3.15E-04 -1.014 
Cell Death cell death 3.42E-08 0.875 
Cell Death apoptosis of phagocytes 9.75E-07 -0.913 
Cell Death apoptosis 2.90E-06 0.648 
Cell Death cell death of lung cell lines 2.03E-05   
Cell Death cell viability 1.41E-04 -0.895 
Cell Death cell death of muscle cells 2.36E-04 0.56 
Cell Death cell death of organ 2.63E-04 0.885 
Cell Death apoptosis of organ 2.86E-04 0.29 
Cell Death apoptosis of lung cell lines 3.34E-04   
Cell Death apoptosis of muscle cells 3.45E-04 0.342 
Cell-To-Cell Signaling & 
Interaction adhesion of granulocytes 5.07E-04 1.465 
Cell-To-Cell Signaling & 
Interaction activation of cells 2.63E-03 1.06 
Cell-To-Cell Signaling & 
Interaction response of granulocytes 4.84E-04 -0.392 
Cellular Assembly & 
Organization disruption of lipid bilayer 1.88E-04   
Cellular Assembly & 
Organization fusion of liposome 2.82E-04   
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Cellular Compromise injury of cells 1.06E-04 -0.261 
Cellular Function & 
Maintenance cellular homeostasis 5.25E-04 1.165 
Cellular Function & 
Maintenance autophagy 3.62E-04 0.607 
Cellular Growth & Proliferation proliferation of immune cells 3.68E-03 -2.182 
Cellular Growth & Proliferation proliferation of muscle cells 6.08E-03 1.581 
Cellular Growth & Proliferation proliferation of lymphocytes 8.17E-03 -1.975 
Cellular Growth & Proliferation growth of cells 4.81E-06 -0.016 
Cellular Movement migration of cells 2.71E-07 1.311 
Cellular Movement leukocyte migration 3.86E-06 1.82 
Cellular Movement 
cell movement of myeloid 
cells 1.10E-05 1.68 
Cellular Movement 
cell movement of 
granulocytes 2.36E-05 1.121 
Cellular Movement chemotaxis of cells 5.03E-05 1.142 
Cellular Movement invasion of cells 1.44E-04 1.001 
Cellular Movement 
cell movement of antigen 
presenting cells 2.31E-04 1.793 
Cellular Movement recruitment of leukocytes 3.66E-03 1.188 
Cellular Movement cell movement 5.53E-07 0.987 
Cellular Movement migration of granulocytes 3.17E-04 0.578 
Free Radical Scavenging 
metabolism of reactive 
oxygen species 1.85E-05 1.655 
Free Radical Scavenging 
generation of reactive oxygen 
species 4.71E-05 1.534 
Free Radical Scavenging synthesis of reactive oxygen 6.23E-05 1.729 
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species 
Inflammatory Response chemotaxis of leukocytes 1.03E-05 1.426 
Inflammatory Response cell movement of neutrophils 2.25E-05 2.036 
Inflammatory Response inflammatory response 2.92E-05 1.652 
Inflammatory Response cell movement of phagocytes 7.17E-05 2.272 
Inflammatory Response chemotaxis of granulocytes 8.05E-05 2.135 
Inflammatory Response chemotaxis of myeloid cells 8.29E-05 2.339 
Inflammatory Response chemotaxis of phagocytes 1.04E-04 1.641 
Inflammatory Response 
cell movement of 
macrophages 1.97E-04 1.877 
Inflammatory Response migration of neutrophils 9.41E-04 1.476 
Inflammatory Response chemotaxis of neutrophils 2.42E-03 2.284 
Inflammatory Response activation of myeloid cells 4.00E-03 1.195 
Inflammatory Response cell movement of monocytes 4.92E-03 1.481 
Inflammatory Response immune response 2.81E-06 0.689 
Inflammatory Response phagocytosis of granulocytes 4.41E-04   
Organismal Injury & 
Abnormalities injury of organ 1.72E-05 -0.021 
Post-Translational Modification N-glycosylation of protein 7.48E-05 
Protein Synthesis degradation of protein 1.02E-06 -0.653 
Protein Synthesis metabolism of protein 4.39E-06 -0.732 
Protein Synthesis damage of protein 1.88E-04 
Small Molecule Biochemistry production of nitric oxide 7.49E-03 -1.821 
Small Molecule Biochemistry 
catabolism of acidic amino 
acid 3.93E-04  
 
 
Page 70 of 118European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Table E4: Ingenuity Pathway Analysis Bio Functions predicted by Fisher’s Exact 
Test as over-represented in CF (p<0.05) with Regulation z-scores >1.0 or <-1.0 (i.e. 
indicating a greater than 2-fold difference). Shaded rows record Bio Functions with a 
high prediction confidence (p<0.0005), but where the predicted Regulation z-score 
indicates a less than 2-fold difference or none could be calculated. 
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UniProt 
Accession 
Gene Name Description GO Biological Processes 
P36222 CHI3L1 Chitinase-3-like protein 1 
activation of NF-kappaB-inducing 
kinase activity; carbohydrate 
metabolic process; inflammatory 
response 
P61160 ACTR2 Actin-related protein 2 cellular component movement 
Q9H9B4 SFXN1 Sideroflexin-1 
erythrocyte differentiation; cellular 
iron ion homeostasis 
P48595 SERPINB10 Serpin B10 regulation of proteolysis 
Q13043 STK4 
Serine/threonine-protein kinase 
4 
induction of apoptosis; negative 
regulation of cell proliferation 
P15498 VAV1 Proto-oncogene vav 
induction of apoptosis by 
extracellular signals; immune 
response; regulation of small 
GTPase mediated signal 
transduction 
Q13636 RAB31 Ras-related protein Rab-31 
Golgi vesicle transport; protein 
transport; small GTPase mediated 
signal transduction 
Q9H4M9 EHD1 EH domain-containing protein 1 
GTP catabolic process; endocytic 
recycling; intracellular protein 
transport 
Q99829 CPNE1 Copine-1 
lipid metabolic process; vesicle-
mediated transport 
P20592 MX2 
Interferon-induced GTP-binding 
protein Mx2 
regulation of cell cycle; regulation 
of nucleocytoplasmic transport 
P57737 CORO7 Coronin-7 
Golgi membrane; cytoplasmic 
membrane-bounded vesicle 
P34059 GALNS 
N-acetylgalactosamine-6-
sulfatase 
carbohydrate metabolic process; 
keratan sulfate catabolic process 
P26038 MSN Moesin 
leukocyte cell-cell adhesion; 
leukocyte migration; regulation of 
lymphocyte migration 
P08473 
MME Neprilysin 
beta-amyloid metabolic process; 
cellular response to cytokine 
stimulus; proteolysis 
Q9P107 
GMIP GEM-interacting protein 
negative regulation of Rho 
GTPase activity 
P07332 
FES Tyrosine-protein kinase Fes/Fps 
regulation of cell proliferation; 
positive regulation of myeloid cell 
differentiation; regulation of mast 
cell degranulation 
Q9NUQ9 
FAM49B Protein FAM49B - 
P98171 
ARHGAP4 
Rho GTPase-activating protein 
4 
Rho protein signal transduction; 
induction of apoptosis by 
extracellular signals; cytoskeleton 
organization 
Q86YV0 
RASAL3 RAS protein activator like-3 
negative regulation of Ras protein 
signal transduction 
Q14005 
IL16 Pro-interleukin-16 
immune response; induction of 
positive chemotaxis; leukocyte 
chemotaxis 
P30153 
PPP2R1A 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform 
inactivation of MAPK activity; 
induction of apoptosis; negative 
regulation of cell growth 
Page 72 of 118European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
P23368 ME2 
NAD-dependent malic enzyme, 
mitochondrial 
malate metabolic process 
Q15080 NCF4 Neutrophil cytosol factor 4 
immune response; phagosome 
maturation; antigen processing 
and presentation of exogenous 
peptide antigen via MHC class I, 
TAP-dependent; cell 
communication 
P12724 RNASE3 Eosinophil cationic protein 
RNA catabolic process; defense 
response to bacterium 
Q8IX19 MCEMP1 
Mast cell-expressed membrane 
protein 1 
- 
A6NI72 NCF1B 
Putative neutrophil cytosol 
factor 1B 
cell communication 
P62834 RAP1A Ras-related protein Rap-1A 
activation of MAPKK activity; 
energy reserve metabolic process; 
small GTPase mediated signal 
transduction 
Q13838 DDX39B 
Spliceosome RNA helicase 
DDX39B 
ATP-dependent helicase activity 
Q5JXB2 UBE2NL 
Putative ubiquitin-conjugating 
enzyme E2 N-like 
- 
Q5TD94 RSPH4A 
Radial spoke head protein 4 
homolog A 
cilium movement 
Q9NQ38 SPINK5 
Serine protease inhibitor Kazal-
type 5 
 
epithelial cell differentiation; 
negative regulation of immune 
response; negative regulation of 
proteolysis 
P10253 GAA Lysosomal alpha-glucosidase 
glucose metabolic process; 
glycogen catabolic process; 
lysosome organization 
Q96TC7 RMDN3 
Regulator of microtubule 
dynamics protein 3 
apoptotic process; cell 
differentiation 
P19013 KRT4  
Keratin, type II cytoskeletal 4 
 
cytoskeleton organization; 
epithelial cell differentiation; 
negative regulation of epithelial 
cell proliferation 
P07858 CTSB Cathepsin B 
autophagy; negative regulation of 
cell death; regulation of apoptotic 
process; proteolysis 
Q5RHP9 ERICH3 
Glutamate-rich protein 3 
- 
Q8N392 ARHGAP18 
Rho GTPase-activating protein 
18 
positive regulation of GTPase 
activity 
Q9NZM1 MYOF  
Myoferlin 
 
plasma membrane repair; 
regulation of vascular endothelial 
growth factor receptor signaling 
pathway 
P02786 TFRC Transferrin receptor protein 1 
cellular iron ion homeostasis; 
proteolysis 
P18124 
RPL7 60S ribosomal protein L7  
structural constituent of ribosome; 
transcription regulator activity; 
translation 
O15031 PLXNB2  Plexin-B2 
positive regulation of GTPase 
activity 
P13686 ACP5 
Tartrate-resistant acid 
phosphatase type 5 
 
response to LPS; negative 
regulation of inflammatory 
response; negative regulation of 
nitric oxide biosynthetic process; 
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negative regulation of superoxide 
anion generation 
Q07954 LRP1 
Prolow-density lipoprotein 
receptor-related protein 1 
apoptotic cell clearance; beta-
amyloid clearance; regulation of 
phospholipase A2 activity; 
regulation of actin cytoskeleton 
organization 
Q14764 MVP  Major vault protein 
cell proliferation; negative 
regulation of protein 
autophosphorylation; negative 
regulation of signaling; protein 
activation cascade; protein 
transport 
Q14204 DYNC1H1  
Cytoplasmic dynein 1 heavy 
chain 1 
antigen processing and 
presentation of exogenous peptide 
antigen via MHC class II; cell 
death; microtubule-based 
movement; stress granule 
assembly 
P01024 C3  Complement C3 
complement activation, alternative 
& classical pathways; 
inflammatory response; negative 
regulation of endopeptidase 
activity; positive regulation of 
activation of membrane attack 
complex; positive regulation of 
angiogenesis; positive regulation 
of glucose transport; positive 
regulation of lipid storage; positive 
regulation of phagocytosis; 
regulation of triglyceride 
biosynthetic process 
 
Table E5: Gene Ontology Biological Processes for proteins detected exclusively in 
the CF cohort (dark red) or the control cohort (dark blue) and proteins up-regulated 
(pale red) or down-regulated (pale blue) in CF relative to controls (Mann-Whitney U 
test; p<0.05).   
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Run Samples 
1 CF1.1, CF1.2, CF1.3, CF2.1, CF2.2, CF2.3 & REF 
2 CF3.1, CF3.2, CF3.3, CF6.1, CF6.2, CF6.3 & REF 
3 CF4.1, CF4.2, CF4.3, CF5.1, CF5.2, CF5.3 & REF 
4 CF7.1, CF7.2, CF7.3, CF11.1, CF11.2, CF11.3 & REF 
5 CF12.1, CF12.2, CF12.3, CF13.1, CF13.2, CF13.3 & REF 
6 CF15.1, CF15.2, CF15.3, CF16.1, CF16.2, CF16.3 & REF 
7 HC23, HC24, HC33, HC35, HC36, HC38 & REF 
8 HC27, HC28, HC29, HC39, HC40, HC41 & REF 
 
Table E6: Samples included per MudPIT run. CF indicates the CF cohort and HC 
the healthy control cohort. The code used to label the CF samples indicates first 
patient ID followed by “.1” for exacerbation pre-antibiotic treatment, “.2” for 
exacerbation post-antibiotic treatment (<24h) and “.3” for stable follow-up (4-15 
weeks following treatment.) Only one sample was collected from each of the health 
controls. 
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Figure E1: Sputum total protein yields (mg per g sputum) for single samples 
collected from healthy controls (HC) and for three samples collected from each 
individual in the CF cohort. The three CF samples were collected: (1) at exacerbation 
before commencement of antibiotic treatment; (2) at completion of antibiotic 
treatment for exacerbation; and (3) during a follow-up period of clinical stability. 
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Figure E2: Median (±IQR) % abundance of myeloperoxidase and lactotransferrin 
per sample as determined by ELISA quantification. For both proteins, median % 
abundance is greater in the CF cohort compared to the healthy control (HC) cohort 
(p<0.05, Mann Whitney U test). 
  
0
0.1
0.2
0.3
0.4
0.5
Lactotransferrin MPO
%
 a
b
u
n
d
a
n
c
e
 b
y
 E
L
IS
A
CF
HC
Page 77 of 118 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
Figure E3: Western Blot validation of mass spectrometry data for azurocidin, heat 
shock protein beta-1 and cytokeratin 13. Relative abundance values were calculated 
as % emPAI from the mass spectrometry data. 
 
Page 78 of 118European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with 
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METHODS 
Extraction of sputum cellular proteins 
All work was carried out at 4°C and using prechilled buffers. Approximately 1g of 
mucus plug was separated from each sputum sample and mixed with 9 ml sterile 
phosphate buffered saline pH 7.4 (PBS) containing Roche Complete Mini protease 
inhibitor cocktail (PIC). The mixture was homogenised thoroughly by repeat syringing 
(no needle) and cells pelleted by centrifugation for 10 min at 4,000 x g. The cells 
were washed twice more in 10 ml PBS+PIC and strained through a 70 µm nylon cell 
strainer (BD Biosciences) to remove any remaining cell clumps. The cells were 
pelleted once more to remove all supernatant before protein extraction. Cell pellets 
were resuspended in 0.2 - 3.0 ml lysis buffer (10 mM HEPES, 0.5 mM EDTA, 1% v/v 
Nonidet P 40, 4% w/v SDS, pH 8.0) depending on pellet size and Sigma protease 
inhibitor cocktail added at 10 µl per 1 ml as directed. After thorough homogenisation 
by vortexing and repeat passage through an 18-gauge needle, the mixtures were 
subjected to 5 freeze-thaw cycles and water bath sonication to ensure lysis. 
Insoluble cell debris was removed by centrifugation at 14,000 x g and the soluble 
protein supernatants were stored at -80°C.  
Protein digestion and iTRAQ labelling 
Protein digestion and iTRAQ labelling were performed as described previously (1). 
Protein concentrations were determined by BCA Protein Assay (Pierce). 
ProteaseMax (Promega) made up in 50 mM triethylammonium bicarbonate (TEAB) 
was added to a final concentration of 0.1% to 70 µg of each protein sample. The 
samples were reduced with 5 mM tris-(2-carboxyethyl) phosphine at 55°C for 20 min 
and alkylated with 10 mM methyl methanethiosulphonate at room temperature for 20 
min. Following methanol/chloroform precipitation for 60 min at 4°C, protein pellets 
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were resuspended in 50 mM TEAB, 0.1% Proteasemax and trypsin digested 
overnight at 37°C. The tryptic peptides were dried to <5 µl by vacuum centrifugation 
and diluted with 500 mM TEAB to a final volume of 30 µl, before acidification with 
trifluoroacetic acid and labelling with 8plex iTRAQ Reagents (AB Sciex) according to 
kit instructions. 
MudPIT 
Six test samples and a reference sample were mixed for simultaneous analysis by 
2D liquid chromatography MudPIT, using a two-dimensional Vented Column Setup 
with a Proxeon nano-flow high-performance liquid pump as described previously (1). 
Eight MudPIT runs were performed in total and the samples combined per run are 
recorded in Table E6. Each salt step was eluted at 3.5 µl/min on an analytical 
column (100 µm internal diameter packed with 12 cm of 5 µm Aqua C18) on line with 
an LTQ Orbitrap Velos (Thermo Electron). Data were acquired in profile mode using 
the following parameters: for full-scan Fourier transform mass spectrometry, 
resolution = 60,000, m/z = 380–1,700 and the 10 most intense ions were fragmented 
with higher-collision dissociation at a normalised collision energy of 40% and an 
activation time of 0.1. Minimum threshold signal was at 5,000 and isolation width at 
1.2. Dynamic exclusion settings were repeat count 1, repeat duration of 30, 
exclusion list size 500, exclusion duration 60 and exclusion mass width 10 p.p.m. 
Protein identification 
Peaklists were generated by Mascot Distiller (Matrix science; version 2.3). Protein 
identification was performed by the Mascot search engine version 2.3 against the 
UniProt human database 2016 (92,179 sequences) plus NCBI non-redundant 
database (2016), taxonomy P. aeruginosa (634,627 sequences) with a precursor 
mass tolerance of 20 p.p.m., with iTRAQ8plex (N-terminal) and iTRAQ8plex (lysine) 
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as fixed modifications and oxidation (methionine) and deamidated (asparagine & 
lysine) as variable modifications. Trypsin was set as the cleavage enzyme and one 
missed cleavage was allowed. A mass tolerance of 0.3 Da was set for fragment ions. 
Mascot Percolator was used to re-score the results to false discovery rates of 0.74-
1.16% for protein identification. Protein identifications with a MOWSE score less than 
65 were rejected. Protein-level iTRAQ ratios were calculated as intensity weighted, 
using only peptides with expectation values less than 0.05. Global ratio normalization 
was performed using intensity summation, with no outlier rejection.  
Enzyme-linked Immunosorbent assay (ELISA) 
In order to validate myeloperoxidase and lactotransferrin as high abundance proteins 
in the CF cohort compared to control cohort and to demonstrate that commercial 
ELISAs are a practical method for validation of candidate biomarkers, both proteins 
were quantified in each sample by ELISA (ab119605 and ab108882 respectively, 
Abcam, Cambridge, UK) according to the manufacturer’s instructions. Figure E2 
shows the median±IQR % abundance for each candidate biomarker along with the 
corresponding data for the control cohort.   
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Western immunoblot 
Western immunoblot was used to further confirm the mass spectrometry 
identification and quantification data (Figure E3). Patient sample protein 
concentrations were assessed by BCA assay (Thermo Scientific Inc., Rockford, 
USA). 25 µg of protein was loaded per lane on 4-20% TGXTM gels and transferred to 
0.45 µm PVDF membrane (Millipore Corproration, Massachusetts, USA) with a 
CriterionTM mini gel tank and blot module, associated buffers and power supply, 
according to the manufacturer’s guidelines (Bio-rad Laboratories Inc., Hercules, 
USA). Nonspecific binding was blocked overnight at 4 °C using 5% non-fat milk in 
PBS with 0.05% Tween 20 (PBST) (Sigma-Aldrich Company Ltd., Gillingham, UK). 
Primary antibodies against azurocidin, heatshock protein beta 1 and cytokeratin 
(Abcam Ltd, Cambridge, UK) were incubated with blotted membranes at a diluted in 
PBST, for 1 h at room temperature. Membranes were washed 3 times (5 min each) 
with PBST and incubated in secondary anti-IgG horseradish peroxidase diluted in 
PBST (Promega Inc., Madison, USA), for 1 h at room temperature. After a further 6 
washes, bands were visualized using Supersignal West Pico chemiluminescent 
substrate (Thermo Scientific Inc., Rockford, USA), imaged with a Autochemi CCD 
camera and analysed with Labworks software version 4.0.0.8 (UVP Ltd., Cambridge, 
UK). 
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DISCUSSION 
A number of proteins detected consistently in CF sputum correlated negatively with 
lung function measured as FEV1 % predicted. Their biological/clinical relevance and 
potential for causing injury are discussed below. Interestingly, 9 out of these 15 
proteins also showed differential abundance in the CF cohort following intravenous 
antibiotic treatment of a pulmonary exacerbation, with the changes in abundance 
bringing them closer to levels in the control cohort. 
Acute inflammation-associated proteins alpha-1-antitrypsin, haptoglobin, fibrinogen 
and alpha-2-macroglobulin have previously been identified as serum biomarkers of 
pulmonary disease including CF and COPD and can be predictive of response to 
treatment and prognosis (2-6). The presence of these proteins in the lungs has 
traditionally been thought to be due to plasma leakage. However, haptoglobin and 
fibrinogen may also be synthesized in the lungs in response to inflammation and 
injury, and may exert roles in immunity and repair mechanisms (7, 8). Alpha-1-
antitrypsin is an inhibitor of neutrophil serine proteases, including elastase, which 
contribute significantly to lung destruction in CF, and therefore its negative 
correlation with lung function might seem surprising. However, previous studies 
observed that plasma deficiencies during inflammation were associated with less 
severe lung disease in CF (9, 10). Fibrinogen has been shown to increase mucin 
production in airway epithelial cells (11), which could contribute to the CF 
hypersecretory phenotype. 
Three proteins associated with the migration of neutrophils, lymphocytes and 
alveolar monocytes – integrin beta 2, vanin-2 and serine/threonine-protein kinase 10 
(12-14) – correlated negatively with lung function.  This correlation could be due to 
either the negative impact of these cells as part of an overactive immune system or 
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poor lung health stimulating an increased influx of immune cells. In accordance with 
the predicted neutrophil influx in CF, four granule proteins – neutrophil elastase, 
olfactomedin-4, CD63 antigen and maltase-glucoamylase – were also found to 
correlate negatively with lung function. Neutrophil elastase exerts antimicrobial 
activity and therefore might be expected to promote lung health. However, CF-
associated accumulation of neutrophil elastase can be damaging to lung tissue (15-
17) and sputum measurements have previously been shown to predict the rate of 
FEV1 decline in children with CF (18), while higher levels of neutrophil elastase 
following antibiotic treatment of an exacerbation have been associated with an 
increased risk of subsequent exacerbation (19). Additionally, serum levels of 
elastase/alpha-1-antitrypsin complex have been found to predict response to 
treatment of chronic P. aeruginosa colonisation (3). In contrast, olfactomedin-4 has 
been shown to down-regulate proinflammatory responses to bacterial infection and 
reduce bacterial killing mediated by granule serine proteinases (20, 21), which would 
be expected to negatively affect lung health. Additionally, olfactomedin-4 has 
recently been identified as a novel target autoantigen for antineutrophil cytoplasmic 
antibodies (ANCA), although both cases reported were for people without CF (22).  
Neprilysin cleaves inflammatory peptides and has been proposed as protective 
against hypoxia- and smoke-related pulmonary vascular remodeling in COPD (23, 
24), while thioredoxin-dependent peroxidase reductase has been implicated as an 
important scavenger of reactive oxygen species during LPS-induced oxidative stress 
and gene knockout mice showed increased lung inflammation (25). Although both 
correlated negatively with lung function, there is no published data suggesting their 
effects can be harmful. Thus, it is likely that observed levels signify a response to 
inflammation rather than a cause. BASP1 is strongly expressed in ciliated respiratory 
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cells (26) and its detection in sputum cells is likely indicative of significant 
dislodgement of these cells and injury to the respiratory tract that would be expect to 
hinder mucus clearance. Additionally, increased BASP1 expression has been linked 
to apoptosis of human tubular epithelial cells and in diabetic nephropathy (27).  
Finally, levels of RhoA also correlated negatively with lung function. As already 
discussed, RhoA is involved in the regulation of many activities relating to 
inflammatory and immune response repair such as phagocytosis, cell migration and 
wound closure. In part its negative correlation with lung function may reflect the 
degree of injury, but also its promotion of neutrophil influx may incur a mechanism 
for tissue damage.  
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Sample type CF phenotype/observation Refs 
human nasal 
epithelial cells 
reduced expression of the anti-inflammatory protein annexin 
A1 in CF 
(28) 
human nasal 
epithelial cells 
differential expression of proteins related to chronic 
inflammation, oxidative stress, cytoskeleton proteins and 
mitochondrial proteins  
(29) 
mouse airway 
epithelial cells 
reduced expression of carbonyl reductase (prostaglandin 
metabolism) and a more pronounced down-regulation of two 
key enzymes of retinoic acid metabolism after injury  
(30) 
human nasal 
epithelial cells  
multiple-biomarker signature patterns for CF  (31) 
human 
bronchial 
epithelial cell 
line 
differences in glycolytic and gluconeogenic pathways, 
unfolded protein responses and a signaling pathway involved 
in cellular calcium homeostasis  
(32) 
human 
bronchial 
epithelial cell 
line 
differential regulation of protein folding and degradation as 
well as differential expression of other proteins likely to relate 
to CF pathology 
(33) 
human 
bronchial 
epithelial cell 
line 
differential regulation of COP9 signalosome, cellular response 
to interleukin-4, response to salt stress, protein binding 
involved in protein folding, cell redox homeostasis & actin 
cytoskeleton 
(34) 
human nasal 
epithelial cells 
impairment of pathways relating to metabolism, G protein 
process, inflammation and oxidative stress response, protein 
folding, proteolysis and structural proteins 
(35) 
human differential enrichment/depletion of innate immunity, (36) 
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bronchial 
epithelial cell 
line secretions 
cytoskeleton/extracellular matrix organization & 
protease/antiprotease activity;  oxidative & classical 
complement pathways altered in vivo were not altered in vitro 
cell-free 
sputum fluid or 
BALF 
distinct CF protein profiles observed  (37-39) 
cell-free BALF less complete cohort clustering for young children with CF 
than for non-CF children with active lung disease 
(40) 
cell-free 
sputum fluid 
2-D gel electrophoresis protein profiles from CF adults 
approached a “healthy” profile after hospitalized treatment  
(38) 
cell-free 
sputum fluid or 
BALF 
increased immune response, proteolytic activity and 
dysregulation of complement in CF  
(38, 39) 
cell-free 
sputum fluid or 
BALF 
identification of CF-associated inflammatory biomarkers and 
autoantigens, including myeloperoxidase, interleukin 8 and 
calgranulins A, B & C  
(37, 38, 
41) 
 
Table E1: Summary of previous proteomic studies of the CF airways. 
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IV abx for treatment of 
current PEx 
long-term oral 
abx 
oral abx 
(previous 30 
days) 
inhaled abx 
(previous 30 
days) 
CF1 
meropenem & 
tobramycin azithromycin - 
tobramycin & 
colistin 
CF2 ceftazidime & tobramycin - - 
tobramycin & 
colistin 
CF3 cefuroxime & colistin azithromycin - tobramycin 
CF4 
piperacillin/ 
tazobactam & tobramycin azithromycin - colistin 
CF5 
piperacillin/ 
tazobactam, aztreonam 
& chlorphenamine - - 
tobramycin & 
colistin 
CF6 
piperacillin/ 
tazobactam & tobramycin azithromycin ciprofloxacin colistin 
CF7 tobramycin & temocillin azithromycin - 
tobramycin & 
colistin 
CF11 
piperacillin/ 
tazobactam & tobramycin - - tobramycin 
CF12 aztreonam & tobramycin azithromycin - 
tobramycin & 
colistin 
CF13 aztreonam & tobramycin azithromycin - colistin 
CF15 aztreonam & tobramycin azithromycin ciprofloxacin colistin 
CF16 
tobramycin, ceftazidime 
& colistin azithromycin N tobramycin 
 
Table E2: Treatment regimens of the CF cohort.  
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UniProt 
Accession 
Gene 
Name 
Description 
Log2 mean 
CF/control 
Signif 
(p) 
Q14764 MVP  Major vault protein 
Reduced in 
CF 
0.002 
P28676 GCA  Grancalcin 2.347 0.000 
P01833 PIGR  Polymeric immunoglobulin receptor -1.467 0.000 
O15144 ARPC2 Actin-related protein 2/3 complex subunit 2 - n.s. 
P52907 CAPZA1  F-actin-capping protein subunit alpha-1 -1.060 0.000 
P05023 ATP1A1 
Sodium/potassium-transporting ATPase 
subunit alpha-1 
- n.s. 
P05091 ALDH2  Aldehyde dehydrogenase, mitochondrial -1.944 0.000 
Q9HD89 RETN  Resistin 1.968 0.000 
P05141 SLC25A5 ADP/ATP translocase 2 - n.s. 
P38606 ATP6V1A  V-type proton ATPase catalytic subunit A -1.586 0.000 
P21281 ATP6V1B2  
V-type proton ATPase subunit B, brain 
isoform 
-1.153 0.000 
Q01518 CAP1  
Isoform 1 of Adenylyl cyclase-associated 
protein 1 
-0.580 0.008 
Q9UM07 PADI4 Protein-arginine deiminase type-4 - n.s. 
Q9Y6N5 SQRDL  
Sulfide:quinone oxidoreductase, 
mitochondrial 
-0.612 0.002 
P13646 KRT13  Isoform 1 of Keratin, type I cytoskeletal 13 -3.704 0.000 
P13667 PDIA4  Protein disulfide-isomerase A4 -0.798 0.000 
P13796 LCP1  Plastin-2 0.362 0.049 
P07237 P4HB  Protein disulfide-isomerase 0.302 0.027 
P48735 IDH2 
Isocitrate dehydrogenase [NADP], 
mitochondrial 
0.551 0.012 
P23368 ME2 
NAD-dependent malic enzyme, 
mitochondrial 
Increased 
in CF 
0.000 
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P07339 CTSD  Cathepsin D -2.120 0.000 
P07384 CAPN1  Calpain-1 catalytic subunit -0.864 0.001 
P23528 CFL1 Cofilin-1 - n.s. 
P41218 MNDA  Myeloid cell nuclear differentiation antigen 1.051 0.000 
P31943 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H - n.s. 
P15924 DSP  Isoform DPI of Desmoplakin -2.154 0.000 
Q15080 NCF4 Neutrophil cytosol factor 4 
Increased 
in CF 
0.000 
Q15149 PLEC  Plectin -1.452 0.000 
P09622 DLD  Dihydrolipoyl dehydrogenase, mitochondrial -0.930 0.000 
Q6P4A8 PLBD1 Phospholipase B-like 1 - n.s. 
P51149 RAB7A  Ras-related protein Rab-7a -0.379 0.022 
P51159 RAB27A Ras-related protein Rab-27A 1.698 0.000 
P00367 GLUD1  Glutamate dehydrogenase 1, mitochondrial -1.568 0.000 
P00403 MT-CO2  Cytochrome c oxidase subunit 2 -0.759 0.006 
P00450 CP  Ceruloplasmin -0.662 0.016 
P43353 ALDH3B1  
Aldehyde dehydrogenase family 3 member 
B1 
-0.878 0.001 
P00505 GOT2  Aspartate aminotransferase, mitochondrial -1.137 0.000 
P43490 NAMPT  Nicotinamide phosphoribosyltransferase 0.797 0.000 
P61626 LYZ  Lysozyme C -0.548 0.002 
P35579 MYH9 Myosin-9 - n.s. 
P27797 CALR Calreticulin - n.s. 
P27824 CANX Calnexin - n.s. 
P10606 COX5B 
Cytochrome c oxidase subunit 5B, 
mitochondrial 
- n.s. 
P10644 PRKAR1A  
cAMP-dependent protein kinase type I-
alpha regulatory subunit 
0.914 0.000 
Q92542 NCSTN Nicastrin - n.s. 
Page 97 of 118 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
P20160 AZU1  Azurocidin 1.693 0.000 
Q6UX06 OLFM4  Olfactomedin-4 1.636 0.000 
P55072 VCP  Transitional endoplasmic reticulum ATPase -1.079 0.000 
P55084 HADHB  
Trifunctional enzyme subunit beta, 
mitochondrial 
-1.211 0.000 
P12273 PIP  Prolactin-inducible protein -1.746 0.000 
Q08380 LGALS3BP  Galectin-3-binding protein -2.038 0.000 
O75131 CPNE3  Copine-3 1.068 0.000 
P30040 ERP29  Endoplasmic reticulum resident protein 29 1.499 0.000 
P12724 RNASE3 Eosinophil cationic protein 
Increased 
in CF 
0.001 
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 
Increased 
in CF 
0.004 
P04792 HSPB1  Heat shock protein beta-1 -3.468 0.000 
P04843 RPN1  
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 precursor 
-1.065 0.000 
P14314 PRKCSH Glucosidase 2 subunit beta - n.s. 
P14625 HSP90B1  Endoplasmin -0.391 0.009 
P40121 CAPG Macrophage-capping protein - n.s. 
O75955 FLOT1  Flotillin-1 0.782 0.001 
P30740 SERPINB1  Leukocyte elastase inhibitor 1.050 0.000 
P14780 MMP9 Matrix metalloproteinase-9 - n.s. 
P22894 MMP8  Neutrophil collagenase 1.777 0.000 
P08311 CTSG Cathepsin G 2.147 0.000 
P61158 ACTR3  Actin-related protein 3 -0.648 0.000 
O60234 GMFG  Glia maturation factor gamma 1.663 0.000 
P50395 GDI2 Rab GDP dissociation inhibitor beta - n.s. 
P40939 HADHA  
Trifunctional enzyme subunit alpha, 
mitochondrial 
-1.428 0.000 
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P00558 PGK1 Phosphoglycerate kinase 1 - n.s. 
P13639 EEF2  Elongation factor 2 -1.224 0.000 
P10599 TXN  Thioredoxin -1.289 0.000 
P07737 PFN1 Profilin-1 - n.s. 
P30038 ALDH4A1 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial 
- n.s. 
P04839 CYBB  Cytochrome b-245 heavy chain 1.197 0.000 
P09917 ALOX5 Arachidonate 5-lipoxygenase - n.s. 
P04083 ANXA1  Annexin A1 -1.957 0.000 
P52209 PGD 
6-phosphogluconate dehydrogenase, 
decarboxylating 
- n.s. 
P27105 STOM  
Erythrocyte band 7 integral membrane 
protein 
1.685 0.000 
P09211 GSTP1  Glutathione S-transferase P -0.741 0.000 
P15144 ANPEP  Aminopeptidase N 0.486 0.007 
Q8WUM4 PDCD6IP Programmed cell death 6-interacting protein - n.s. 
Q12913 PTPRJ  
Receptor-type tyrosine-protein 
phosphatase eta precursor 
0.621 0.006 
P40926 MDH2  Malate dehydrogenase, mitochondrial -1.000 0.000 
Q8TDL5 BPIFB1 BPI fold-containing family B member 1 -1.470 0.003 
Q14739 LBR Lamin-B receptor - n.s. 
P49913 CAMP  Cathelicidin antimicrobial peptide precursor 1.215 0.002 
Q8IX19 MCEMP1 Mast cell-expressed membrane protein 1 
Increased 
in CF 
0.000 
Q9Y2J8 PADI2  Protein-arginine deiminase type-2 0.915 0.005 
P39656 DDOST  
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
-0.909 0.001 
Q13576 IQGAP2  Ras GTPase-activating-like protein IQGAP2 0.546 0.001 
P80188 LCN2  Neutrophil gelatinase-associated lipocalin 1.806 0.000 
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Q15084 PDIA6 Protein disulfide-isomerase A6 -0.570 0.035 
P21333 FLNA  Isoform 2 of Filamin-A -0.897 0.000 
P50990 CCT8  T-complex protein 1 subunit theta -0.833 0.000 
P06576 ATP5B  ATP synthase subunit beta, mitochondrial -1.416 0.000 
A6NI72 NCF1B  Putative neutrophil cytosol factor 1B 
Increased 
in CF 
0.000 
P10909 CLU  Clusterin -2.856 0.000 
P69905 
HBA1 & 
HBA2 
Hemoglobin subunit alpha - n.s. 
P07355 ANXA2  Isoform 2 of Annexin A2 -2.744 0.000 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A - n.s. 
P25705 ATP5A1  ATP synthase subunit alpha, mitochondrial -0.751 0.010 
P62805 
HIST1H4F/
HIST1H4C;
HIST1H4A;
HIST1H4I;
HIST1H4B;
HIST2H4B;
HIST1H4L;
HIST1H4E;
HIST1H4D;
HIST1H4J;
HIST1H4K;
HIST1H4H;
HIST2H4A;
HIST4H4  
Histone H4 1.775 0.000 
Q14204 DYNC1H1  Cytoplasmic dynein 1 heavy chain 1 
Reduced in 
CF 
0.001 
P06733 ENO1  Alpha-enolase -0.694 0.002 
P04040 CAT  Catalase 1.108 0.000 
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P14618 PKM Pyruvate kinase PKM - n.s. 
P13489 RNH1  Ribonuclease inhibitor -0.549 0.001 
P01011 SERPINA3 Alpha-1-antichymotrypsin 0.548 0.048 
P01009 SERPINA1  Alpha-1-antitrypsin 1.036 0.001 
P29401 TKT Transketolase 0.955 0.000 
P22314 UBA1 Ubiquitin-like modifier-activating enzyme 1 - n.s. 
P37837 TALDO1  Transaldolase -0.581 0.019 
O75083 WDR1 WD repeat-containing protein 1 - n.s. 
P01024 C3  Complement C3 
Reduced in 
CF 
0.020 
Q14254 FLOT2 Flotillin-2 - n.s. 
P50995 ANXA11  Annexin A11 1.198 0.000 
Q5JTV8 TOR1AIP1  Torsin-1A-interacting protein 1 -0.511 0.001 
O43451 MGAM  Maltase-glucoamylase, intestinal 2.495 0.000 
P36222 CHI3L1 Chitinase-3-like protein 1 CF only n.a. 
P61160 ACTR2 Actin-related protein 2 CF only n.a. 
Q9H9B4 SFXN1 Sideroflexin-1 CF only n.a. 
P48595 
SERPINB1
0 
Serpin B10 CF only n.a. 
Q13043 STK4 Serine/threonine-protein kinase 4 CF only n.a. 
P15498 VAV1 Proto-oncogene vav CF only n.a. 
Q13636 RAB31 Ras-related protein Rab-31 CF only n.a. 
Q9H4M9 EHD1 EH domain-containing protein 1 CF only n.a. 
Q99829 CPNE1 Copine-1 CF only n.a. 
P20592 MX2 
Interferon-induced GTP-binding protein 
Mx2 
CF only n.a. 
P57737 CORO7 Coronin-7 CF only n.a. 
P34059 GALNS N-acetylgalactosamine-6-sulfatase CF only n.a. 
P26038 MSN Moesin CF only n.a. 
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P08473 MME Neprilysin CF only n.a. 
Q9P107 GMIP GEM-interacting protein CF only n.a. 
P07332 FES Tyrosine-protein kinase Fes/Fps CF only n.a. 
Q9NUQ9 FAM49B Protein FAM49B CF only n.a. 
P98171 ARHGAP4 Rho GTPase-activating protein 4 CF only n.a. 
Q86YV0 RASAL3 RAS protein activator like-3 CF only n.a. 
Q14005 IL16 Pro-interleukin-16 CF only n.a. 
P30153 PPP2R1A 
Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha isoform 
CF only n.a. 
P62834 RAP1A Ras-related protein Rap-1A control only n.a. 
Q07954 LRP1 
Prolow-density lipoprotein receptor-related 
protein 1 
control only n.a. 
P02786 TFRC Transferrin receptor protein 1 control only n.a. 
Q9NZM1 MYOF  
Myoferlin 
 
control only n.a. 
P10253 GAA Lysosomal alpha-glucosidase control only n.a. 
P07858 CTSB Cathepsin B control only n.a. 
Q5JXB2 UBE2NL 
Putative ubiquitin-conjugating enzyme E2 
N-like 
control only n.a. 
Q96TC7 RMDN3 
Regulator of microtubule dynamics protein 
3 
control only n.a. 
P13686 ACP5 
Tartrate-resistant acid phosphatase type 5 
 
control only n.a. 
Q5TD94 RSPH4A Radial spoke head protein 4 homolog A control only n.a. 
Q5RHP9 ERICH3 Glutamate-rich protein 3 control only n.a. 
P18124 RPL7 60S ribosomal protein L7  control only n.a. 
Q9NQ38 SPINK5 
Serine protease inhibitor Kazal-type 5 
 
control only n.a. 
Q8N392 ARHGAP1 Rho GTPase-activating protein 18 control only n.a. 
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8 
Q13838 DDX39B Spliceosome RNA helicase DDX39B control only n.a. 
P19013 KRT4  
Keratin, type II cytoskeletal 4 
 
control only n.a. 
O15031 PLXNB2  Plexin-B2 control only n.a. 
 
Table E3: Proteins detected in all 48 sputum samples or all samples belonging to at 
least one cohort. Where independent samples T-tests identified differential 
abundance between the cohorts (p<0.05) the log2 ratio of mean abundance levels 
and significance are recorded. Where Mann-Whitney U Tests identified differential 
abundance (p<0.05) increased or decreased abundance in CF is recorded along with 
significance. No significant difference in abundance between the cohorts is recorded 
as “-“. 
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Functions Category Bio Functions Annotation 
Confidence  
level  
(p-value) 
Regulation  
z-score 
Cell Death apoptosis of neutrophils 3.56E-09 -1.308 
Cell Death apoptosis of myeloid cells 6.85E-07 -1.108 
Cell Death killing of cells 6.31E-05 1.88 
Cell Death cell survival 3.15E-04 -1.014 
Cell Death cell death 3.42E-08 0.875 
Cell Death apoptosis of phagocytes 9.75E-07 -0.913 
Cell Death apoptosis 2.90E-06 0.648 
Cell Death cell death of lung cell lines 2.03E-05   
Cell Death cell viability 1.41E-04 -0.895 
Cell Death cell death of muscle cells 2.36E-04 0.56 
Cell Death cell death of organ 2.63E-04 0.885 
Cell Death apoptosis of organ 2.86E-04 0.29 
Cell Death apoptosis of lung cell lines 3.34E-04   
Cell Death apoptosis of muscle cells 3.45E-04 0.342 
Cell-To-Cell Signaling & 
Interaction adhesion of granulocytes 5.07E-04 1.465 
Cell-To-Cell Signaling & 
Interaction activation of cells 2.63E-03 1.06 
Cell-To-Cell Signaling & 
Interaction response of granulocytes 4.84E-04 -0.392 
Cellular Assembly & 
Organization disruption of lipid bilayer 1.88E-04   
Cellular Assembly & 
Organization fusion of liposome 2.82E-04   
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Cellular Compromise injury of cells 1.06E-04 -0.261 
Cellular Function & 
Maintenance cellular homeostasis 5.25E-04 1.165 
Cellular Function & 
Maintenance autophagy 3.62E-04 0.607 
Cellular Growth & Proliferation proliferation of immune cells 3.68E-03 -2.182 
Cellular Growth & Proliferation proliferation of muscle cells 6.08E-03 1.581 
Cellular Growth & Proliferation proliferation of lymphocytes 8.17E-03 -1.975 
Cellular Growth & Proliferation growth of cells 4.81E-06 -0.016 
Cellular Movement migration of cells 2.71E-07 1.311 
Cellular Movement leukocyte migration 3.86E-06 1.82 
Cellular Movement 
cell movement of myeloid 
cells 1.10E-05 1.68 
Cellular Movement 
cell movement of 
granulocytes 2.36E-05 1.121 
Cellular Movement chemotaxis of cells 5.03E-05 1.142 
Cellular Movement invasion of cells 1.44E-04 1.001 
Cellular Movement 
cell movement of antigen 
presenting cells 2.31E-04 1.793 
Cellular Movement recruitment of leukocytes 3.66E-03 1.188 
Cellular Movement cell movement 5.53E-07 0.987 
Cellular Movement migration of granulocytes 3.17E-04 0.578 
Free Radical Scavenging 
metabolism of reactive 
oxygen species 1.85E-05 1.655 
Free Radical Scavenging 
generation of reactive oxygen 
species 4.71E-05 1.534 
Free Radical Scavenging synthesis of reactive oxygen 6.23E-05 1.729 
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species 
Inflammatory Response chemotaxis of leukocytes 1.03E-05 1.426 
Inflammatory Response cell movement of neutrophils 2.25E-05 2.036 
Inflammatory Response inflammatory response 2.92E-05 1.652 
Inflammatory Response cell movement of phagocytes 7.17E-05 2.272 
Inflammatory Response chemotaxis of granulocytes 8.05E-05 2.135 
Inflammatory Response chemotaxis of myeloid cells 8.29E-05 2.339 
Inflammatory Response chemotaxis of phagocytes 1.04E-04 1.641 
Inflammatory Response 
cell movement of 
macrophages 1.97E-04 1.877 
Inflammatory Response migration of neutrophils 9.41E-04 1.476 
Inflammatory Response chemotaxis of neutrophils 2.42E-03 2.284 
Inflammatory Response activation of myeloid cells 4.00E-03 1.195 
Inflammatory Response cell movement of monocytes 4.92E-03 1.481 
Inflammatory Response immune response 2.81E-06 0.689 
Inflammatory Response phagocytosis of granulocytes 4.41E-04   
Organismal Injury & 
Abnormalities injury of organ 1.72E-05 -0.021 
Post-Translational Modification N-glycosylation of protein 7.48E-05 
Protein Synthesis degradation of protein 1.02E-06 -0.653 
Protein Synthesis metabolism of protein 4.39E-06 -0.732 
Protein Synthesis damage of protein 1.88E-04 
Small Molecule Biochemistry production of nitric oxide 7.49E-03 -1.821 
Small Molecule Biochemistry 
catabolism of acidic amino 
acid 3.93E-04  
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Table E4: Ingenuity Pathway Analysis Bio Functions predicted by Fisher’s Exact 
Test as over-represented in CF (p<0.05) with Regulation z-scores >1.0 or <-1.0 (i.e. 
indicating a greater than 2-fold difference). Shaded rows record Bio Functions with a 
high prediction confidence (p<0.0005), but where the predicted Regulation z-score 
indicates a less than 2-fold difference or none could be calculated. 
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UniProt 
Accession Gene Name Description GO Biological Processes 
P36222 CHI3L1 Chitinase-3-like protein 1 
activation of NF-kappaB-inducing 
kinase activity; carbohydrate 
metabolic process; inflammatory 
response 
P61160 ACTR2 Actin-related protein 2 cellular component movement 
Q9H9B4 SFXN1 Sideroflexin-1 erythrocyte differentiation; cellular iron ion homeostasis 
P48595 SERPINB10 Serpin B10 regulation of proteolysis 
Q13043 STK4 Serine/threonine-protein kinase 4 
induction of apoptosis; negative 
regulation of cell proliferation 
P15498 VAV1 Proto-oncogene vav 
induction of apoptosis by 
extracellular signals; immune 
response; regulation of small 
GTPase mediated signal 
transduction 
Q13636 RAB31 Ras-related protein Rab-31 
Golgi vesicle transport; protein 
transport; small GTPase mediated 
signal transduction 
Q9H4M9 EHD1 EH domain-containing protein 1 
GTP catabolic process; endocytic 
recycling; intracellular protein 
transport 
Q99829 CPNE1 Copine-1 lipid metabolic process; vesicle-
mediated transport 
P20592 MX2 Interferon-induced GTP-binding protein Mx2 
regulation of cell cycle; regulation 
of nucleocytoplasmic transport 
P57737 CORO7 Coronin-7 Golgi membrane; cytoplasmic 
membrane-bounded vesicle 
P34059 GALNS N-acetylgalactosamine-6-
sulfatase 
carbohydrate metabolic process; 
keratan sulfate catabolic process 
P26038 MSN Moesin 
leukocyte cell-cell adhesion; 
leukocyte migration; regulation of 
lymphocyte migration 
P08473 MME Neprilysin 
beta-amyloid metabolic process; 
cellular response to cytokine 
stimulus; proteolysis 
Q9P107 GMIP GEM-interacting protein negative regulation of Rho GTPase activity 
P07332 FES Tyrosine-protein kinase Fes/Fps 
regulation of cell proliferation; 
positive regulation of myeloid cell 
differentiation; regulation of mast 
cell degranulation 
Q9NUQ9 FAM49B Protein FAM49B - 
P98171 ARHGAP4 Rho GTPase-activating protein 4 
Rho protein signal transduction; 
induction of apoptosis by 
extracellular signals; cytoskeleton 
organization 
Q86YV0 RASAL3 RAS protein activator like-3 negative regulation of Ras protein 
signal transduction 
Q14005 IL16 Pro-interleukin-16 
immune response; induction of 
positive chemotaxis; leukocyte 
chemotaxis 
P30153 PPP2R1A 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform 
inactivation of MAPK activity; 
induction of apoptosis; negative 
regulation of cell growth 
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P23368 ME2 NAD-dependent malic enzyme, 
mitochondrial malate metabolic process 
Q15080 NCF4 Neutrophil cytosol factor 4 
immune response; phagosome 
maturation; antigen processing 
and presentation of exogenous 
peptide antigen via MHC class I, 
TAP-dependent; cell 
communication 
P12724 RNASE3 Eosinophil cationic protein RNA catabolic process; defense 
response to bacterium 
Q8IX19 MCEMP1 Mast cell-expressed membrane protein 1 - 
A6NI72 NCF1B Putative neutrophil cytosol factor 1B cell communication 
P62834 RAP1A Ras-related protein Rap-1A 
activation of MAPKK activity; 
energy reserve metabolic process; 
small GTPase mediated signal 
transduction 
Q13838 DDX39B Spliceosome RNA helicase DDX39B ATP-dependent helicase activity 
Q5JXB2 UBE2NL Putative ubiquitin-conjugating 
enzyme E2 N-like - 
Q5TD94 RSPH4A Radial spoke head protein 4 homolog A cilium movement 
Q9NQ38 SPINK5 
Serine protease inhibitor Kazal-
type 5 
 
epithelial cell differentiation; 
negative regulation of immune 
response; negative regulation of 
proteolysis 
P10253 GAA Lysosomal alpha-glucosidase 
glucose metabolic process; 
glycogen catabolic process; 
lysosome organization 
Q96TC7 RMDN3 Regulator of microtubule dynamics protein 3 
apoptotic process; cell 
differentiation 
P19013 KRT4  Keratin, type II cytoskeletal 4 
 
cytoskeleton organization; 
epithelial cell differentiation; 
negative regulation of epithelial 
cell proliferation 
P07858 CTSB Cathepsin B 
autophagy; negative regulation of 
cell death; regulation of apoptotic 
process; proteolysis 
Q5RHP9 ERICH3 Glutamate-rich protein 3 - 
Q8N392 ARHGAP18 Rho GTPase-activating protein 18 
positive regulation of GTPase 
activity 
Q9NZM1 MYOF  Myoferlin 
 
plasma membrane repair; 
regulation of vascular endothelial 
growth factor receptor signaling 
pathway 
P02786 TFRC Transferrin receptor protein 1 cellular iron ion homeostasis; proteolysis 
P18124 RPL7 60S ribosomal protein L7  
structural constituent of ribosome; 
transcription regulator activity; 
translation 
O15031 PLXNB2  Plexin-B2 positive regulation of GTPase 
activity 
P13686 ACP5 
Tartrate-resistant acid 
phosphatase type 5 
 
response to LPS; negative 
regulation of inflammatory 
response; negative regulation of 
nitric oxide biosynthetic process; 
Page 109 of 118 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
negative regulation of superoxide 
anion generation 
Q07954 LRP1 Prolow-density lipoprotein 
receptor-related protein 1 
apoptotic cell clearance; beta-
amyloid clearance; regulation of 
phospholipase A2 activity; 
regulation of actin cytoskeleton 
organization 
Q14764 MVP  Major vault protein 
cell proliferation; negative 
regulation of protein 
autophosphorylation; negative 
regulation of signaling; protein 
activation cascade; protein 
transport 
Q14204 DYNC1H1  Cytoplasmic dynein 1 heavy 
chain 1 
antigen processing and 
presentation of exogenous peptide 
antigen via MHC class II; cell 
death; microtubule-based 
movement; stress granule 
assembly 
P01024 C3  Complement C3 
complement activation, alternative 
& classical pathways; 
inflammatory response; negative 
regulation of endopeptidase 
activity; positive regulation of 
activation of membrane attack 
complex; positive regulation of 
angiogenesis; positive regulation 
of glucose transport; positive 
regulation of lipid storage; positive 
regulation of phagocytosis; 
regulation of triglyceride 
biosynthetic process 
 
Table E5: Gene Ontology Biological Processes for proteins detected exclusively in 
the CF cohort (dark red) or the control cohort (dark blue) and proteins up-regulated 
(pale red) or down-regulated (pale blue) in CF relative to controls (Mann-Whitney U 
test; p<0.05).   
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Run Samples 
1 CF1.1, CF1.2, CF1.3, CF2.1, CF2.2, CF2.3 & REF 
2 CF3.1, CF3.2, CF3.3, CF6.1, CF6.2, CF6.3 & REF 
3 CF4.1, CF4.2, CF4.3, CF5.1, CF5.2, CF5.3 & REF 
4 CF7.1, CF7.2, CF7.3, CF11.1, CF11.2, CF11.3 & REF 
5 CF12.1, CF12.2, CF12.3, CF13.1, CF13.2, CF13.3 & REF 
6 CF15.1, CF15.2, CF15.3, CF16.1, CF16.2, CF16.3 & REF 
7 HC23, HC24, HC33, HC35, HC36, HC38 & REF 
8 HC27, HC28, HC29, HC39, HC40, HC41 & REF 
 
Table E6: Samples included per MudPIT run. CF indicates the CF cohort and HC 
the healthy control cohort. The code used to label the CF samples indicates first 
patient ID followed by “.1” for exacerbation pre-antibiotic treatment, “.2” for 
exacerbation post-antibiotic treatment (<24h) and “.3” for stable follow-up (4-15 
weeks following treatment.) Only one sample was collected from each of the health 
controls. 
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Figure E1: Sputum total protein yields (mg per g sputum) for single samples 
collected from healthy controls (HC) and for three samples collected from each 
individual in the CF cohort. The three CF samples were collected: (1) at exacerbation 
before commencement of antibiotic treatment; (2) at completion of antibiotic 
treatment for exacerbation; and (3) during a follow-up period of clinical stability. 
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Figure E2: Median (±IQR) % abundance of myeloperoxidase and lactotransferrin 
per sample as determined by ELISA quantification. For both proteins, median % 
abundance is greater in the CF cohort compared to the healthy control (HC) cohort 
(p<0.05, Mann Whitney U test). 
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Figure E3: Western Blot validation of mass spectrometry data for azurocidin, heat 
shock protein beta-1 and cytokeratin 13. Relative abundance values were calculated 
as % emPAI from the mass spectrometry data. 
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Figure 1: Distribution and relative abundance of human proteins detected in sputum samples collected from 
CF and healthy control cohorts. A. shows that 119 proteins were found in all 48 samples, i.e. both CF and 
control, while a further 21 proteins were found exclusively in all CF samples and 17 proteins exclusively in 
all control samples. B. shows hierarchical clustering (using Euclidean distance dissimilarity and McQuitty’s 
linkage criteria) of individual sputum samples according to the relative abundance levels for all 119 
consistently detected proteins. CF and control samples largely cluster separately with the only exceptions 
being 2 CF samples (marked with black arrows) collected after antibiotic treatment for pulmonary 
exacerbation. The scale is a log2 ratio of relative abundance.  
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Figure 2: Differential activity of Canonical Pathways in consensus CF and control proteomes.  Based on the 
set of proteins detected in all samples within a cohort, Ingenuity Pathway Analysis software applied Fisher’s 
Exact Test to predict the Canonical Pathways likely to be active within that cohort (p<0.05). The top 5 
pathways predicted in the control cohort concern general metabolism, clatherin-mediated endocytosis 
signaling and mitochondrial dysfunction and these were detected with approximately equal probabilities in 
both cohorts. Pathways where there is a >5-fold increase in p-value in the CF proteome compared to the 
control proteome, indicating likely up-regulation in CF are involved in immune functions including neutrophil 
recruitment, rearrangement of the actin cytoskeleton, phagocytosis and T cell signaling.  
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Figure 3: Ingenuity Pathway Analysis predicted network for proteins detected in CF involved in Inflammatory 
Response and Cell Movement Bio Functions. The intensity of red or green shading indicates the degree of 
increased or decreased abundance in CF relative to healthy controls, respectively. A red outline with no 
internal shading indicates that the protein was detected exclusively in the CF cohort. The network identifies 
LPS as a likely inflammatory trigger.  
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Figure 4: Relative abundance estimates (% emPAI median ± IQR) for proteins comprising >1% of total 
human proteins in >80% of CF samples. Human Protein Atlas (26) annotations for protein expression in 
terms of tissue location and localised abundance are recorded. H, M and L indicate high, medium and low 
protein expression. All proteins are either highly or moderately expressed in bone marrow hematopoietic 
cells, 50% of which are myelopoietic cells, and all except cathepsin G are moderately or lowly expressed in 
lung macrophages.  
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